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ABSTRACT 
A STATIN-REGULATED MICRORNA REPRESSES C-MYC EXPRESSION AND 
FUNCTION 
APANA AGHA L. TAKWI 
NOVEMBER 1, 2011 
c-Myc dysregulation is one of the most common abnormalities found in human cancer. 
MicroRNAs (miRNAs) are functionally intertwined with the c-Myc network as multiple 
miRNAs are regulated by c-Myc, while others directly suppress c-Myc expression. In 
this work, we identified miR-33b as a primate-specific negative regulator of c-Myc. The 
human miR-33b gene is located at 17pl1.2, a genomic locus frequently lost in 
medulloblastomas, which are pediatric brain tumors that display c-Myc overproduction. 
Through a small-scale screening with drugs approved by the US Food and Drug 
Administration (FDA), we found that lovastatin up-regulated miR-33b expression, 
reduced cell proliferation, and impaired c-Myc expression and function in miR-33b-
positive medulloblastoma cells. In addition, a low dose oflovastatin treatment at a level 
comparable to approved human oral use reduced tumor growth in mice orthotopically 
xenografted with cells carrying miR-33b, but not with cells lacking miR-33b. This work 
presents a highly promising therapeutic option, using drug repurposing and a miRNA as a 
biomarker, against cancers that over-express c-Myc. 
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CHAPTER 1 
MICRORNA REGULATION AND MEDULLOBLASTOMA DEVELOPMENT 
1.1. INTRODUCTION 
The most common pediatric malignancies are leukemia/lymphoma (40%) and primary 
central nervous system (CNS) tumors (30%). There are very few genetic changes 
identified in childhood malignancies e.g. fewer p53 mutations. These changes often arise 
in embryonal precursor cells where aberrant signaling in normal development (1). 
Despite advances in recent years that have resulted in an improvement in the survival rate 
of childhood cancers (80%), these cancers still remain the most common cause of 
childhood death due to disease in western countries (2). 
1.2. CHILDHOOD BRAIN TUMORS 
Collectively, tumors of the brain are the most common solid tumors and most chemo-
resistant neoplasms of childhood and adolescence. Malignant tumors of the brain account 
for 21 % of all cancers and 24% of all cancer-related deaths in this age group. They 
account for 4.3 cases per 100,000 people yearly in the U.S. and are among the leading 
causes of cancer-related morbidity and mortality during childhood (3, 4). CNS tumors 
show diverse histologies, location and survival. Treatment regiments for brain tumors 
involve surgery, radiation and chemotherapy. Complications as a result of treatment are 
of significant concern, as long term side effects are common in surviving patients (5). 
Tumors of the CNS are classified based on the World Health Organization (WHO) 
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classification system of biological behavior of tumors, which includes a grading scale 
corresponding to aggressiveness (6). The malignancy scale is crucial for determining 
adequate therapies. In children these grades are from Grade I to Grade IV, where Grade.! 
applies to lesions that have low proliferative potential and that are often correlated with 
good prognosis. Grade IV applies to high-proliferative, mitotically active cells and is 
often associated with fatal outcomes (6). A further sub-division exists whereby tumors 
are grouped based on the site of origin and type of cells. The most common childhood 
CNS tumors are located in the posterior fossa: astrocytoma (44%), medulloblastoma 
(19%) and ependynoma (10%) (7). 
1.2.1. Treatment 
Standard therapy for brain tumors consists of surgery followed by radiation to the entire 
craniospinal axis with boosts to both the primary tumor site and focal CNS metastatic 
sites. Following diagnosis, location and histology (type and grade) of the tumor 
determine if the tumor is surgically accessible. Improved techniques such as functional 
imaging and diffusion tensor imaging help the surgeon map the brain and define tracts 
and connections, leading to better tumor resection management and less harm to normal 
tissues (8). Low grade glioma is completely resected and no further treatment is needed. 
Medulloblastoma and ependymoma, on the other hand, are often only partially resected 
through surgery. In such cases radiation and chemotherapy are necessary after surgery 
(9). 
The most common radiation technique is craniospinal radiotherapy (CSRT). Patients 
treated with CSRT receive radiation to the craniospinal axis with an additional boost to 
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the tumor. Novel radiation techniques are available and are in clinical trials including 
conformal radiation therapy (CRT) that incorporates three-dimensional CT and MRI 
imaging, allowing more precise planning and delivery, which helps to identify the tumor 
and surrounding critical structures. 
A variety of chemotherapeutic agents are effective against CNS tumors, including 
platinum compounds, nitrosureas, cyclophosphamide, iphosphamide, temozolomide, 
etoposide and vincristine. Children who have undergone both chemotherapy and 
radiation therapy have a significantly higher survival rate. Chemotherapy eligibility 
depends on the type and stage of tumor, and age of the patient. In children younger than 
3years with unresectable tumors, chemotherapy is used to delay radiation therapy or, at 
best, reduce the dose while trying to maintain high cure rates. Combinatorial 
chemotherapy is considered most effective when used with surgery and radiation 
treatment to control local and disseminated disease (9). 
1.2.2. Late Effects 
Late effects are likely the result of the complex interactions between the tumor, different 
treatment modalities and individual characteristics in a growing and developing child (7). 
Patients receiving radiation therapy are at risk of developing side effects that negatively 
affect cognitive, endocrine and neurological functions (5). Radiation has been reported to 
cause neuro-endocrine abnormalities, personality changes and neuro-cognitive sequelae 
for surviving children (5). Reduced IQ has been reported for children receiving whole 
brain radiation (10, 11); while endocrine sequelae depend on dose of radiation and age of 
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the patient. Patients receiving as low as 16 gray (Gy) acquire damage to the 
hypothalamic-pituitary axis with abnormalities in production of growth hormones (12). 
Patients receiving higher doses, >40gy, develop endocrine and reproductive dysfunction 
(e.g. decreased production of thyroid and follicle stimulating hormones, 
adrenocorticotrophic hormone, and luteinizing hormone) (12). 
1.3. MEDULLOBLASTOMA 
Medulloblastoma is the second most frequent brain tumor in children after pilocytic 
astrocytoma. Most medulloblastomas occur in the first decade of life (13, 14). 
Medulloblastoma is an embryonal tumor of the brain, analogous to Wilms tumor of the 
kidney and adrenal neuroblastoma (15). Its embryonal nature is underlined by its high 
incidence in infants and children and by its undifferentiated, immature appearance, which 
resembles developing neural tissue (15). It is a densely cellular, midline cerebellar tumor 
that arises over the roof of the fourth ventricle (15). Despite debates over its origin and 
nomenclature, medulloblastoma is grouped under the name primitive neuroectodermal 
tumors (PNET) because it was thOUght historically that all embryonic tumors originated 
from a common precursor cell of the subependymal matrix in the eNS (15). Gene 
profiling technologies have demonstrated that embryonic brain tumors are a 
heterogeneous group of neoplasms and that these tumors should be classified based on 
tumor location, histology and patterns of differentiation (16). Increasing evidence suggest 
that medulloblastoma may originate from precursor cells (e.g. granule cells) in the 
external granular layer (EGL) of the cerebellum (16, 17). The development of 
medulloblastoma follows a specific sequence of events [(18), Fig. 1]. The less aggressive 
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classic and desmoplastic medulloblastoma subtypes generally arise upon constitutive 
activation of wingless (Wnt) or sonic hedgehog (Shh) signaling. Subsequent activation of 
MYC, through gene amplification or over-expression, coupled with chromosome 17p loss 
gives rise to the more aggressive, metastatic large cell/anaplastic medulloblastoma 
(Fig. 1). Most medulloblastoma appear sporadically except for a small fraction of patients 
that harbor germ-line mutations in tumor suppressor genes, such as those in Gorlin 
syndrome (19) and Turcot syndrome (20). 
1.3.1. Histopathology 
Based on histopathology, medulloblastoma are divided in four SUbtypes: classical 
medulloblastoma, desmoplastic/nodular medulloblastoma, medulloblastoma with 
extensive nodularity (MBEN) and large/anaplastic medulloblastoma [LAIC, (6, 21)]. Two 
tissue patterns are also identified: medulloblastoma with myogenic differentiation 
(medullomyoblastoma) and medulloblastoma with melanotic differentiation (melanocytic 
medulloblastoma) (6). 
Classic medulloblastoma accounts for 65% of cases and is composed of diffused masses 
of small, undifferentiated oval or round cells. Desmoplastic medulloblastoma account for 
25% of cases and comprise of firm and consistent stroma made-up of recticulin-free 
nodule surrounded by proliferative cells. MBEN accounts for 5% of cases and differs 
exhibits a markedly expanded lobular architecture and advanced neuronal differentiation. 
The LAIC subtype accounts for 5% of cases and are characterized by spherical cells that 
have large nuclei, open chromatin and prominent nuclei. 
5 
External granule Layer cells 






MYCN or over-e)(pression 
htert 
17p toss 
,~ PDGFR Activation 
large cell/anaplastic 
medulloblastoma 
Fig. 1: Schematic representation of the molecular progression of medulloblastoma 
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1.4. MEDULLOBLASTOMA ETIOLOGY 
1.4.1. A Change in Normal Development? 
It is accepted that there is a link between embryonic development and the biology of 
embryonic tumors (22). Many genes that were initially identified as oncogenes and tumor 
suppressor genes have been identified as the key regulators of normal developmental 
events. This is particularly true in embryonic tumors of the CNS (22). The majority of 
these genes regulate the components of Wnt and Shh signaling pathways which activate 
c-Myc. It is also clear that many of the pathways required for cerebellum development 
are activated in medulloblastoma (16, 17). 
1.4.1.1. Wnt Signaling 
The Wnt signaling pathway (Fig. 2) is a critical regulator of stem cell (SC) self renewal 
and is essential for proper embryonic development. It tightly controls intercellular 
communication in mUltiple developmental events and has been implicated in several 
diseases, particularly cancer (23,24). The Wnt cascade regulates cell proliferation, cell 
fate specifications and cell differentiation through its major effector B-catenin (23). The 
stability of B-catenin is regulated by the destruction complex that induces adenomatous 
polyposis coli (APC), Axin, glycogen synthase kinase-3B (GSK-3 B) and casein kinase 1a 
(CK1a). In the absence of the Wnt ligand, the two scaffolding proteins APC and Axin 
bind newly synthesized B-catenin. GSK-3B and CK1a then phosphorylate a set of 
conserved Ser and Thr residues on B-catenin. This results in the ubiquitination and 
degradation of B-catenin by the proteosome (23,25). Upon activation of the Wnt ligand, 
the family of seven transmembrane Frizzle (Fz) receptors is engaged with the low-density 
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lipoprotein (LDL) receptor related protein (LRP) complex, Lrp5/6. Binding of Wnt to the 
FZ-LRP facilitates reconfiguration of the FZ transmembrane domain. The intracellular 
proteins Dishevelled (Dsh) and Axin are recruited to the cell membrane, and 
phosphorylation of the cytoplasmic compartment of LRP occurs. In addition, relocation 
of Axin to the membrane leads to inhibition of B-catenin phosphorylation and subsequent 
inactivation of the destructive complex. This elevates cytoplasmic B-catenin protein 
levels, causing B-catenin to enter the cell nucleus, where it interacts with members of the 
T cell factor/lymphoid enhancer factor (TcflLef) family of transcription factors. In the 
absence of Wnt signaling, TcflLef interacts with Groucho and histone deacetylases such 
as Rpd3 to act as repressor of Wnt target genes (26). The binding of B-catenin to TcflLef 
relieves the repressive activity of Groucho, and thus activates Tcf target genes such as 
cellular myelocytomatosis virus related oncogene (c-Myc) and cyclin D1 [(23,25), Fig. 
2]. Activation of Wnt signaling pathway is found in up to 25% of sporadic 
medulloblastoma (27). For instance, mutations in components of the Wnt pathway, such 
as CTNNBq (encoding B-catenin), APC and Axin, have been demonstrated in 
approximately 15% of sporadic medulloblastomas (28-30). Several studies using gene 
expression arrays have shown that Wnt signaling is activated in a distinct molecular 
subset of medulloblastomas (16, 31, 32). 
1.4.1.2. Sonic Hedgehog (Shh) Signaling 
Shh signaling is known to regulate growth and patterning during embryonal development. 
Recent data suggest that Shh signaling is essential for SC maintenance and regeneration 
(33). Germ-line mutations that affect Shh signaling activity are associated with 
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developmental disorder, whereas mutations activating the pathway are linked to multiple 
forms of cancer including medulloblastoma (34). In the absence of Shh, the 12-span 
transmembrane cell surface receptor Patched (Ptch) acts to inhibit the activity of the 7-
span transmembrane receptor-like protein Smoothened (Smo). Lack of Smo activity 
results in phosphorylation of Gli2/Gli3, which is further sequestered in the cytoplasm, 
where Gli2/Gli3 forms a complex with Fused and Costal2. Subsequently, Gli3 is 
recognized by ~-TrCP and proteolytic ally processed to generate the truncated repressor 
form GliR. This truncated form of Gli3 represses a subset of Shh target genes (33). The 
binding of Shh to Patched releases inhibitory activity of Smo, which triggers the activity 
of Gli2 (GliA) by inhibiting the major intracellular inhibitor of Gli, Suppressor of fused. 
Free GliA can trans locate to the nucleus and activate the expression of target genes such 
as MYC, Cyclin D1, Gli-1and Patched [(33), Fig. 2]. Godin syndrome, in which patche 
(Ptch) is mutaed, is an autosomal dominant disorder that predisposes individuals to 
developmental defects and cancer. About 1-2% of medulloblastoma are attributed to the 
syndrome (35). Abnormal Shh signaling activity occurs in approximately 20% of 
sporadic medulloblastomas (31, 32). 
1.4.1.3. Other Important Signaling Pathways in Medulloblastoma Etiology 
c-MET (MET or MNNG HOS) is a proto-oncogene that encodes a protein known as 
hepatocyte growth factor receptor [(HGFR) (36)] the only known ligand for the MET 
receptor. MET is activated by it ligand HGF eventually leads to phosphorylation and 
activation of the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K) or 
indirectly through the scaffolding protein Gab1(37). 
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Aberrantly active MET triggers tumor growth, angiogenesis and metastasis, and this 
correlates with poor prognosis in cancer. MET regulates tumor growth, angiogenesis and 
metastasis, and this correlates with poor prognosis of cancers. MET is deregulated in 
many types of human malignancies, including medulloblastoma. HGF induces tumor cell 
proliferation, anchorage-independent growth, and cell cycle progression beyond the G1-S 
checkpoint (38). HGF also protects medulloblastoma cells against apoptosis induced by 
chemotherapy. This cytoprotective effect was associated with reduction of pro-apoptotic 
cleaved poly (ADP-ribose) polymerase and cleaved caspase-3 proteins and required PI3K 
activity (39). HGF induces MYC mRNA and c-Myc protein in established and primary 
, medulloblastoma cells. 
Myc has emerged as an important prognostic indicator and modulator of 
medulloblastoma malignancy. It is central to the activity of the Shh, Wnt, c-Met and 
insulin growth factor (lGF) pathways which are usually deregulated in medulloblastoma 
(31). 
1.4.2. Biological and Genetic Marker 
The neurotrophin-3 (NT-3) receptor TRKC was the first TRK used as a marker to predict 
clinical outcome, and now several TRKs have been correlated with survival in 
medulloblastoma patients. NT -3 activates TRKC and regulates proliferation, 
differentiation and cell death of the granule cells of the developing cerebellum. High 
TRKC mRNA expression is associated with a favorable outcome in medulloblastoma, 
with 5yr free survival rate of 89 % vs 46% for low TRKC mRNA expression (40). 
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Patients with deregulated Wnt signaling belong to a distinct molecular sub-group of 
medulloblastoma (27, 41). Medulloblastoma with Wnt activation are usually associated 
with chromosomal loss of 6p (41). Patients with ~-catenin necleopositivity have a better 
overall survival (OS) rate compared to patient without Wnt activation, 92% vs 65% (27, 
41). Genetic abnormalities of Shh signaling, as seen in response to mutated Ptchl (the 
Shh receptor which acts as a repressor in the absence of the ligand), are responsible for 
Godin syndrome, which exhibits high medulloblastoma incidence (42). Mutation of Shh 
negative regulators, such as Ptch 1, SuFu and RenlKCTD 11 have all been reported in 
sporadic medulloblastoma. Mutations in these upstream regulators have also been shown 
to regulates Shh target genes including MYC (17, 43). Genomic amplification of MYC 
and the neuroblastoma-derived MYCN is strongly correlated to poor prognosis [5 yr as: 
amplified MYC 13% vs not amplified 72% (44,45)]. Low expression of MYC rnRNA 
indicates a good prognosis, particularly when found in combination with high TRKC 
expression (46). 
The most characteristic chromosomal abnormalities in medulloblastoma are 17p deletion 
and 17 q gain. Approximately 30% of medulloblastoma patients harbor at least one of 
these abnormalities (44). The 5yr as for 17q gain (55%) and isochromosome (35%) are 
better predictors of outcome than 17p deletions [78% (44)]. 
1.5. MYC ONCOGENE 
1.5.1. Gene and Protein Product 
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The MYC gene was originally identified in avian retroviruses as an oncogene responsible 
for inducing myelocytomatosis in birds (47). Its human homologue, c-Myc, was found to 
be evolutionarily conserved (48). In mammals, there are four related genes in the family, 
c-Myc, N-Myc, L-Myc and S-Myc, with all sharing similar structural framework. c-Myc 
is a proto-oncogene and is located on chromosome 8q24.21. The gene product is a 
nuclear phosphoprotein with a short half-life of 20-30 mins that is subsequently 
ubiquitinated for proteosome degradation (49). 
1.5.2. c-Myc as a Transcription Factor 
MYC is a basic Helix-Loop-Helix leucine zipper (bHLHZip) protein that heterodimerize 
with Max, another bHLHZip protein, with binding ability to consensus 5' -CAC[Cff] 
GTG-3'DNA sequences called E-boxes. The basic region promotes sequence-specific 
DNA binding; the HLHZip domain confers protein-protein interaction while the Zip 
domain functions in maintaining dimerization. It is believed that Myc exerts its main 
functions through gene regulation by recruiting transcriptional cofactors involved in 
modulation of RNA polymerase II function and chromatin structure, including histone 
acetyl transferase (HAT) and transformation/transcription domain-associated protein 
(TRRAP) recruitment. These are engaged through interactions with the conserved Myc-
box 2 (MB2) in the transactivation domain (TAD) or with the bHLHZip domain (50-52). 
While the MB2 domain (spanning residues 128-143) is required for cell transformation 
(49,53), the MB1 domain (residues 47-62) is required for c-Myc activity and degradation 
(51,54). MB3 plays a role in cellular transformation and MB4 in Myc-induced focus 
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formation (55). All four MBs are found in both c-Myc and N-Myc, whereas L-Myc lacks 
MB3 (56). 
1.5.3. Downstream Effects of c-Myc 
MYC protein product is a transcription factor that regulates the expression of -15% of all 
genes in the cell. Due to the plethora of target genes c-Myc regulates, it is viewed as a 
multifunctional protein with the ability to regulate activities such as cell cycle, growth 
and metabolism, differentiation, apoptosis, transformation, genomic instability and 
angiogenesis (50, 51). 
1.5.3.1. Cell Cycle and Differentiation 
As Myc is essential for GO/G 1 to S-phase cell cycle progression, cells with activated Myc 
have a shortened Gl phase (57, 58). Myc abrogates the transcription of cell cycle 
checkpoint genes (for example, Gadd45a and Gadd153) and inhibits the function of 
cyclin-dependent kinase (CDK) inhibitors, either through directly repressing gene 
transcription or indirectly through degradation or sequestration. Myc also promotes cell 
cycle progression by activation of cyclin Dl, cyclin D2, and cyclin A, as well as Cdk4, 
cell division cycle 25A (CDC25A), and E2 promoter binding factor (E2F) 112 (59,60). 
Some examples of c-Myc target genes are ornithine decarboxylase (ODC), and Cyclin E 
(50,61). Ornithine decarboxylase (ODC) controls polyamine biosynthesis which is 
essential as s modifier of ion transport channels, regulate protein translation, Okazaki 
fragment joining during DNA replication and progression through S phase of cell cyclin 
(62). Cyclin E, with its partner kinase Cdk2, regulates the G 1 to S-phase transition and 
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promotes DNA replication (63). c-Myc mediated ODC and Cyclin E up-regulation may 
contribute to an oncogenic phenotype as ODC over-expression in mouse fibroblasts 
results in transformation (64). 
MYC has also been found to be important during cellular differentiation. Down-
regulation of Myc is required for cells to exit the cell cycle and undergo differentiation. 
This important point of regulation is further enforced by the induction and function of the 
Mxd family members in response to differentiation cues (57, 65). 
1.5.3.2. Cell Growth/Proliferation 
The ability of Myc to promote cell growth has been demonstrated in vitro and in vivo. 
Myc enables cell growth by providing the cell with an abundant supply of several classes 
of basic building blocks as well as increasing cell metabolism and protein synthesis (66). 
Myc-induced cell proliferation is potentiated by several Myc target genes, including those 
associated with cellular metabolism, ribosomal and mitochondrial biogenesis, and protein 
and nucleic acid synthesis (67, 68). Gadd45a and ODC are specific c-Myc targets that 
have been implicated in c-Myc-mediated cell growth and proliferation. Equally, c-Myc 
has been shown to down-regulate both basal and stress-induced Gadd45 expression (69). 
Gadd45a has been shown to function in growth arrest and in apoptosis following 
genotoxic stress (70). 
1.5.3.3. Genomic Instability 
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S. Mai and colleagues showed that specific gene amplification occurs at a high frequency 
in cells with deregulated Myc (71). Additional research shows that Myc can promote 
chromosomal instability (72, 73). However, the role of Myc in genomic instability has 
been a subject of debate and controversy (74). Several mechanisms have been proposed, 
including increased levels of reactive oxygen species, alterations in chromosome 
structure (75), overcoming the p53 checkpoint (75), and induction of a DNA damage 
response and/or replication (76). Losing the high-fidelity organization of the genome is a 
hallmark of tumorigenesis that can clearly be associated with Myc deregulation. 
1.5.3.4. Metastasis and Angiogenesis 
Down-regulation of thrombospondin is vital to angiogenesis and is potentially achieved 
through Myc induction of the miR-17 -92 cluster (77). The role of Myc expression during 
normal development is associated with proliferative expansion and cellular migration. 
Recent reports have demonstrated that c-Myc expression is required for the activation and 
expression of miR-9 (78-80). miR-9 negatively regulates E-cadherin, which results in 
activation of ~-catenin and in tum contributes to cell metastasis and angiogenesis (80). 
The relevance to tumorigenesis is intuitive, with deregulated MYC preventing 
differentiation and promoting migration, leading to the features of aggressive, less 
differentiated, metastatic cancers. 
1.5.3.5. Induction of Apoptosis 
One of the functions of Myc is induction of apoptosis in response to cellular stress. 
Cyclin A and ODC are central to c-Myc-mediated apoptosis. Inhibition of ODC blocks 
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inhibits apoptosis in c-Myc-over expressing cells, and forced expression of Cyclin A is 
sufficient to induce apoptosis under low serum conditions (81). c-Myc-mediated 
apoptosis correlates with regulation of the Fas receptor and its ligand as well as 
proapoptotic Bax (82). Despite modest change in Bax levels upon c-Myc over-
expression (83), Bax appears to be essential for c-Myc-mediated apoptosis by indirect up-
regulation of upstream molecules like Caspase 8 (84). Furthermore, in response to c-Myc 
activation and MYClRas-induced transformation, p53 can be up-regulated and stabilized 
to induce cell cycle arrest or apoptosis (85). Furthermore, c-Myc-mediated apoptosis 
might be due to accumulation of reactive oxygen species (ROS) as a consequence of NF-
KB inhibition (86). 
1.5.3.6. Regulation of 'Sternness' 
Experiments in transgenic mice have revealed that expression of c-Myc is essential for 
normal developmental control of haematopoietic stem cells (HSC) and neural stem cells 
(87, 88). Knockout of MYC in immature HSCs results in pancytopenia and rapid lethality 
(89). Likewise, c-Myc is crucial for self-renewal and maintenance of pluripotency in 
murine ES cells (90). More evidence demonstrating the importance of c-Myc in 
'sternness' comes from experiments where murine and human somatic cells were 
reprogrammed to pluripotency through the generation of induced pluripotent stem cells 
(iPS) by retrovirus-mediated introduction of Oct3/4, Sox2, Klf4 and c-Myc (91). 
Although a recent report shows that c-Myc may be redundant in the conversion of 
somatic cells to iPS cells (92), there is still an implication for a novel 'sternness' function 
of c-Myc that may be important for controlling tumor-initiating cells. The pluripotent 
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ability of c-Myc has been connected to its ability to positively regulate the cell cycle 
machinery (93). Consistently, down-regulation of c-Myc correlated with the 
differentiation of pluripotent cells (90). 
1.5.4. MYC in Medulloblastoma 
Over-expression of c-Myc in medulloblastoma has been associated with poor prognosis 
and the prognostically dismal large cell/anaplastic medulloblastoma subtype (94-96). Shh 
signaling corporate with c-Myc to enhance tumorigenicity of Nestin-expressing neural 
progenitors that are present in the cerebellum at birth. The Nestin-expressing neural 
progenitor cells can act as the cells-of-origin for medulloblastoma (97). c-Met induces c-
Myc, which mediates medulloblastoma cell proliferation, cell cycle progression, 
apoptosis and increased cell size (39). In cultured granule neuron precursor (GNP) cells, 
insulin growth factor (IGF) signaling stabilizes Myc by inhibiting GSK3p-dependent 
phosphorylation, thus preventing degradation of Myc. Similarly, Myc can substitute for 
IGF signaling in a mouse model of Shh-induced medulloblastoma (98). Therefore, Myc 
appears to playa central role in mediating the effects of the signaling pathways in 
medulloblastoma including Shh, Wnt, c-Met, and IGFR. Therefore, it represents an 
attractive target for the therapy of this neoplasm, especially the very aggressive large 
cell/anaplastic subtype. Unfortunately, clinically useful inhibitors of Myc are not 
available to date. 
Over-expression of c-Myc is found in -31-64% of medulloblastoma patients (96), but 
only 5-15% of them have MYC gene amplification (94, 99, 100). Various means of 
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amplification-independent c-Myc activation have been identified in other human cancers: 
chromosomal translocations in Burkitt's lymphoma constitutively activate mRNA 
expression (101); c-Myc expression in multiple myeloma are increased 20-fold by a 
mutation in the 5' untranslated internal ribosome entry segment (102); mutations at the 
Myc intron factor binding site in mucosa-associated lymphoid tissue lymphomas removes 
a negative regulatory sequence (103); and APC or ~-catenin mutations in colon cancer 
activate the c-Myc promoter at a ~-cateninITcf-4 transcription factor binding site (104). 
APC and ~-catenin mutations have also been found in a small fraction of 
medulloblastoma (30), and nuclear ~-catenin staining was reported in 18% of 
medulloblastoma studied (29). Therefore, genomic amplification-independent activation 
of c-Myc is a likely mechanism for tumor progression of medulloblastoma. 
1.5.5. Regulation of MYC 
In normal cells Myc expression and activity is regulated at multiple levels. At the 
transcriptional level, Myc is regulated by signal transduction pathways that are activated 
both during normal development and in cancer. The most important include Shh, Wnt, 
Notch, RTK signaling and transforming growth factor (TGF)-~. Posttranslationally, c-
Myc is regulated through sequential and reversible phosphorylation at two conserved 
sites, threonine 58 (T58) and serine 62 (S62), located on the amino-terminal TAD of the 
protein (54). T58 phosphorylation stimulates ubiquitination and proteasomal degradation 
by SCFFBW7 (105), while S62 phosphorylation stabilizes c-Myc. It has been hypothesized 
that GSK-3~-mediated phosphorylation of c-Myc at T58 and dephosphorylation at S62 
allows for binding of ubiquitin ligase FBW7 and recruitment of SCFFBW7 complex to 
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direct c-Myc degradation. Coupled to FBW, F-box protein Skp2 and Hect H9 are two 
other ligases involved in c-Myc turnover (106). Skp2 effects transcriptional activation 
and degradation (107) while Hect H9 promotes transcriptional activity only (106). 
Proteins such as Ras, frequently altered in human cancers, can lead to inhibition of GSK-
3~ activity and subsequent stabilization of c-Myc protein through loss of T58 
phosphorylation (108). GSK-3~ acts as a key protein in the canonical Wntl~-catenin 
signaling pathway by regulating the activity and nuclear transportation of ~-catenin, 
which subsequently leads to transactivation of MYC (104). 
1.6. MicroRNA (miRNA) 
MiRNAs are small non-coding RNAs (18-25 nuc1eotides), involved in repression of gene 
expression by binding to the mRNA 3 'untranslated region (3' UTR), and effecting either 
translational repression, or mRNA degradation in animals, plants and protozoa. In 
mammals miRNAs are predicted to control the expression of more than 60% of all 
protein-coding genes (109), and are thereby involved in nearly all cellular processes. 
1.6.1. miRNA Biogenesis 
Individual miRNAs can be transcribed separately from a single transcriptional unit, 
which can encode a single miRNA or a cluster of distinct miRNAs; or they can be 
processed directly from other RNA species, such as introns (Fig. 3). Transcription of 
miRNAs by RNA polymerase II results in primary miRNA transcripts (pri-miRNAs), 
which are 5' capped and polyadenylated at the 3' end. The pri-miRNAs transcript is then 
cleaved in the nucleus by Drosha, an RNase III endonuclease, in association with 
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DGCR8IPasha, the double-stranded RNA-binding domain protein, in a complex known 
as the microprocessor complex (110). Drosha cleaves both strands of the stem at sites 
near the base of the primary stem-loop to generate an intermediate called precursor 
miRNA (pre-miRNA). The pre-miRNA is exported out of the nucleus with the aid of the 
nuclear membrane bound export in 5. In the cytosol the RNase III domain-containing 
nuclease, Dicer, cleaves the terminal loop to generate the -22 nucleotide mature miRNA. 
Dicer functions in combination with the double-stranded RNA-binding domain protein 
TRBP and PACT (111). The mature double-stranded RNA duplex that results from Dicer 
cleavage is unwound and then loaded into the RNA-induced silencing complex (RISC). 
RISC is a complex composed of Dicer, TRBP and a protein of the argonaute superfamily 
(112). The complex identifies target mRNA based on sequence complementarity between 
the miRNA and the associated single-stranded mRNA's 3'UTR, resulting in either 
mRNA cleavage or translational repression (113). Two basic mechanism have been 
proposed for miRNA gene silencing: initiation block, where the miRISC inhibits 
translation initiation by interfering with the eIF4F-cap recognition and 40S small 
ribosomal subunit recruitment or by antagonizing 60S subunit joining and preventing 80S 
ribosomal complex formation (114); and post-initiation block, where the miRISC inhibit 
translation by inhibiting ribosome elongation, inducing ribosome drop-off, or facilitating 
proteolysis of nascent polypeptide (115). 
1.6.2. miRNAs and Cancer 
About 50% of annotated human miRNAs are mapped in fragile regions of chromosomes, 
which are areas of the genome prone to 'genomic earthquakes, that can trigger 
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chromosome rearrangement, disrupt genes and alter gene regulation. These genomic 
regions are associated with various human cancers (116-118). The relevance of miRNAs 
to cancer is highlighted by their differential expression patterns in cancerous cells 
compared to normal cells. Several miRNAs have emerged as candidate components of 
oncogene and tumor-suppressor networks. The miR-17-92 cluster (119, 120), and miR-
155IBIC (121) have been implicated as proto-oncogenes in B-celllymphomas. On the 
other hand, let-7 tumor suppressive function has been validated in various cancers (122, 
123). Many of the oncogenic or tumor-suppressor miRNAs target cell cycle regulators, 
and this interaction may at least partially explain the oncogenic function of the miRNA 
alteration in cancer cells. miRNAs act as oncogenes and tumor suppressor genes and 
induce all of the six hallmarks of malignant cells. 
1.6.2.1. Self-sufficiency in Growth Signals 
To become independent from external growth factor signals and evade tissue 
homeostasis, tumor cells activate different pathways to sustain cell proliferation and 
survival such as the RAS proteins, H-RAS, K-RAS, and N-RAS. RAS oncogenic 
signaling is activated in response to decreased levels of let-7, a well-documented post-
transcriptional RAS regulator that is inversely correlated with RAS expression in solid 
and hematologic malignancies (122). Let-7 down-regulation is associated with poor 
prognosis in lung cancer patients (124) and head and neck squamous cell carcinoma 
patients (125). Let-7 acts as a tumor suppressor by targeting oncogenes such as RAS and 
HMGA2 and is down-regulated in many solid cancers (126). 
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Reduced Let-7expression result in up-regulation of the high-mobility group AT -hook 2 
(HMGA2), which helps tumor cells grow in an anchorage-independent manner and not 
undergo apoptosis after they lose contact with the basal membrane. The clinical relevance 
oflet-Ts anti-proliferative effects was recently demonstrated by let-7-induced tumor 
regression in in vivo murine lung cancer models (124). Also, miR-21, one of the most 
frequently up-regulated miRNAs in solid tumors, also participates in RAS oncogenic 
signaling. API that acts downstream of RAS transcriptionally induce miR-21 which 
exerts its oncogenic effect by keeping phosphatase and tens in homolog (Pten) and 
PDCD4 in check (127). PDCD4, in turn negatively controls API, thus API-induced miR-
21 represents a positive feedback loop that sustains API activity in response to RAS 
(127). miR-21 overexpression enhances tumorigenesis, and genetic deletion of this 
oncogenic miRNA partially protects against tumor formation in transgenic mice (128, 
129). 
1.6.2.2. Insensitivity to Anti-Growth Signals 
The retinoblastoma (RB) pathway is one of the major cell cycle regulatory routes that is 
altered in almost all human cancer cells (130). RB is a transcriptional repressor that 
inhibits members the E2F family, resulting in proliferative arrest and inhibition of the 
expression of genes required for cell cycle progression such as MYC. The RB pathway is 
defective in a wide range of human tumors, resulting in deregulated and hyperactive E2F 
in transformed cells and uncontrolled cell proliferation (131). E2F transcription factor 
activities are controlled at the post-transcriptional level by a series of miRNAs including 
miR-17-5p, miR-20a, miR-106b, and miR-92 (119,132,133). Furthermore, E2F-
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activating transcription factors have been shown to regulate the expression of miRNAs 
(132, 133). Unbound E2F increases miR-17-92 and miR-106b-25 expression which in 
turn keeps E2F levels in check through miR-17-5p and miR-20a (119), thereby 
participating in the delicate equilibrium between cell proliferation and apoptosis. Up-
regulated miRNAs from these clusters target apoptotic and growth inhibitory proteins 
such as BIM and p21 (132). Under physiologic conditions, the miR-17-92 cluster limits 
MYC activation by dampening the E2F positive feedback loop. In tumors with MYC 
activation, the miR-17-92 cluster protects cells from Myc-induced apoptotic E2F 
response, leading to uncontrolled cellular proliferation. Also, miR-106b-25 family 
members are found to be induced in gastric cancer (132) and negatively regulate 
excessively high E2F1 expression levels that cause tumor cell apoptosis. miRNAs also 
play roles in activating cell cycle progression by targeting cell cycle checkpoint proteins. 
The miR -15a-16-1 cluster induces cell cycle arrest at G 1 phase by targeting critical cell 
cycle regulators such as CDK1, CDK2 and CDK6 as well as cyclins (D1, D3 and El) 
(134, 135). In fact, these major cell cycle kinase complexes are regulated by several other 
miRNAs. CDK4 or CDK6 mRNAs are targeted by miR-24, miR-34a, miR-124, miR-
125b, miR-129, miR-137, miR-195, miR-449 and let-7 family members (136, 137). As 
expected, most of these miRNAs display anti-proliferative properties, function as tumor 
suppressors and are inactivated in cancer by different mechanisms (138). Finally, some 
cell cycle inhibitors of the INK4 or Cip/Kip families are also tightly regulated by 
miRNAs. p16INK4a, a CDK4/6 specific inhibitor, is controlled by miR-24 and miR-31 
(139). Both miRNAs are involved in the regulation of cell proliferation and progress 
24 
through the cell cycle at least in part by regulating the levels of the p16INK4a CDK 
inhibitor. 
1.6.2.3. Apoptosis 
Apoptosis is a physiologic self-destruction mechanism that leads to the removal of 
unwanted cells. P53 is the most widely studied transcription factor; it controls the 
expression of several genes to promote tumor suppression. p53 responds to diverse 
cellular stresses and regulates target genes involved in DNA integrity, cell cycle arrest at 
the G 1/S checkpoint, and apoptosis. It is the most commonly mutated gene in human 
cancer. miRNAs such as miR-34, miR-192/215, miR-107, and miR-145 are known 
transcriptional targets of p53 (140). The cancer-associated genomic region 1p36, which is 
lost or rearranged in many tumor types, including those from neural, epithelial, and 
hematopoietic tissues, contains the candidate tumor suppressor miR-34a. The miR-34 
family is composed of three evolutionarily conserved members: miR-34a, miR-34b, and 
miR-34c. miR-34a functions as a potent suppressor of cell proliferation by modulating 
E2F signals (141) and induces p53 in a cell-type specific manner to activate apoptosis. 
Other major pro-apoptotic miRNAs with reduced expression in tumors include the miR-
15a/16-1 cluster, which represses anti-apoptotic Bcl2 protein and activates the intrinsic 
apoptotic program APAF-1-caspase-9-poly (ADP-ribose) polymerase (142). miR-15a and 
miR-16-1 are clustered on human chromosome 13q14, which is frequently lost or down-
regulated in B-cell chronic leukemia and several solid tumor types (142). 
1.6.2.4. Limitless Replicative Potential 
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Cellular senescence is a physiologic withdrawal from the cell cycle in response to a 
multitude of different stress stimuli, including oncogene activation, and telomere 
deregulation (143). It is executed by two important cell cycle inhibitors, p21 and p16 
(144) which are activated upon cellular stress. Also, various stresses can induce 
senescence, but p53 and RB have been identified as critical pathways common to the 
initiation, execution, and maintenance of senescence-associated growth arrest. P53-
activated miRNAs such as miR-34 are also important in senescence by modulating the 
E2F signaling pathway (145, 146). Furthermore, 15 miRNAs have been found to be 
down-regulated in senescent cells and breast cancers harboring wild-type p53, which 
demonstrated that these miRNAs are repressed by p53 in an E2F1-mediated manner 
(147). Recently, the protein subunit TERT of telomerase was found to be a direct target 
of regulation by miRNAs such as miR-138, miR-143, and miR-146a (148, 149). 
1.6.2.5. Angiogenesis 
Tumor cells tum on an "angiogenic switch" to produce large amounts of pro-angiogenic 
factors and promote vascularization. Hypoxia adaptation is an essential cellular response 
that is controlled by vascular endothelial growth factor (VEGF), which is also regulated 
by the oxygen-sensitive master transcription factor hypoxia-inducible factor 1 (HIF-1). 
HIF-1 expression is controlled by specific miRNAs such as the p53-induced miR-107 and 
miR-92 that target the Von Hippel-Lindau gene whose product is responsible for HIF-1 
degradtation (150, 151); it, in tum, controls the expression of other miRNAs (152-154) 
that fine-tune adaptation to low oxygen tension. In tumor progression, hypoxia has been 
found to contribute to the modulation of miRNA expression, partly by direct HIF-1 
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transcriptional activation of specific miRNAs such as miR-424 and miR-210 (152-154). 
These miRNAs have dual functions: they participate in the angiogenic process while 
helping the cell engage anti-apoptotic programs that sustain survival. miR-126 expression 
was found to be enriched in endothelial cells during angiogenesis and to repress negative 
regulators of the VEGF pathway (SPRED1 and PIK3R2) (155). miRNAs that are down-
regulated in hypoxic conditions, such as miR-16, miR-15b, miR-20a, and miR-20b, 
directly modulate VEGF expression levels. This creates a positive feed-forward loop in 
which hypoxia-repressed miRNAs reinforce the expression levels of a potent pro-
angiogenic hypoxia-induced growth factor, such as VEGF (156). Lastly, individual 
miRNAs in the miR-17-92 cluster have effects on angiogenesis with miR-17-5p, miR-
19a and miR-18a contributing directly to angiogenesis (157). 
1.6.2.6. Invasion and Metastasis 
The metastatic process involves multiple steps which culminate in tumor cells spreading 
to distant organs. The deregulation of epithelial-to-mesenchymal transition gives cells 
migratory and invasive properties that promote the dissemination of tumor cells and 
metastasis. Recent studies have shown that members of the miR-200 family (miR-141, 
miR-429, miR-200a, miR-200b, and miR-200c) are essential regulators of differentiation 
and epithelial cell character through the targeting of the zinc finger E-box-binding 
homeobox (Zeb) family of transcription factors (158, 159). Zeb1 and Zeb2 are master 
regulators of the mesenchymal phenotype and repress the transcription of genes 
containing E-box elements in their promoters, including E-cadherin. Twist, a metastasis-
promoting transcription factor, was found to induce miR-lOb expression, whereas 
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HOXDlO, a homeobox transcription factor that promotes or maintains a differentiated 
phenotype in epithelial cells, is found to be a miR-lOb target that is expressed at low 
levels in metastatic tumors (160). miR-21 does not only control cell survival and 
proliferation; it is also a master regulator of the metastatic process by directly modeling 
the cell cytoskeleton via TPM1 suppression (161, 162) and by indirectly regulating the 
expression of the pro-metastatic uP AR (via Maspin and PDCD4 direct suppression) 
(161), matrix metalloproteinases (via RECK and TIMP3) (163), and Pten direct 
suppression (164). 
1.6.3. Chemotherapeutic Importance of miRNAs 
RNA-based gene therapy can be used to treat cancer in two ways: by using RNA 
molecules against the mRNA of genes involved in cancer pathogenesis; or by directly 
targeting the miRNAs that participate in pathogenesis. It is recently reported that 
therapeutic miRNA delivery suppresses tumorigenesis in a murine liver cancer model: 
hepatocellular carcinoma cells exhibit reduced expression of miR-26a and systemic 
administration of miR-26a in a mouse model of hepatocellular carcinoma using adeno-
associated virus results in inhibition of cancer cell proliferation, induction of tumor-
specific apoptosis, and dramatic protection from disease progression without toxicity 
(165). Antagomirs are therapeutic RNA molecules that were originally designed to inhibit 
miRNAs (166, 167). Antagomirs' anti-cancer activity was demonstrated in a 
neuroblastoma model in which cholesterol conjugated antagomir-17 -5p delivery resulting 
in regression of neuroblastoma in 30% of cases (168). Another method of targeting 
miRNAs is through locked nucleic acid (LNA)-mediated miRNA silencing. Efficient 
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miR-122 silencing was achieved with three doses of 10 mg/kg LNA-anti-miRNA. MiR-
122 is an abundant liver specific miRNA, implicated in fatty acid and cholesterol 
metabolism and hepatitis C replication leading. The LNA-miR-122 be exhibited a long-
lasting and reversible decrease in total plasma cholesterol and no evidence of associated 
toxicities or histopathologic changes in the liver (169). Despite the promising result, the 
use of miRNA therapy has not been successful in humans due to constrains such the large 
size of miRNAs or anti-miRNA thereby failing one of the Lipinski rule of five for drug-
likeliness. In addition the molecules are likely recognized as foreign and elicit immune 
responses. Furthermore, miRNAs are expected to have low stability in vivo since they can 
be degraded by endogenous RNases. 
1.6.4. miRNAs and Medulloblastoma 
Peirson and associates were the first to demonstrate that miRNA could regulate 
medulloblastoma development. They showed that miR-124, a brain enriched miRNA, 
was significantly down-regulated in medulloblastoma and augmentation of miR-124 
reduced medulloblastoma cell growth by targeting CDK6 (136). Since then, roles have 
been attributed to miRNAs in modulation of the Shh signaling and Notch (170). For 
example, RES1, the principal Notch-responsive gene, has been shown to be negatively 
regulated by miR-199b-5p, resulting in reduce cell proliferation and migration of 
medulloblastoma cells (171). Moreover, other investigators have focused on miRNA 
profiling of medulloblastoma cell lines in various cellular states and have identified 
important miRNA signature patterns in medulloblastoma development (172, 173). These 
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experiments have all highlighted the importance of miRNA in medulloblastoma 
development and their therapeutic potential. 
1.6.5. Myc-miRNA Regulatory Network 
The transcription factor, c-Myc, also controls the production of many non-coding RNAs, 
including tRNA, rRNA and miRNAs. These RNAs are likely to contribute to the 
complex biology and pathology that is associated with changes in c-Myc expression 
(174). MYC and miRNAs form complex network, with a number of miRNAs reported to 
target MYC and c-Myc regulating the expression some miRNAs. J.T. Mendell and 
coworkers reported the direct induction of the miR-17-92 cluster by c-Myc (119). This 
cluster of six miRNAs is an oncogene and cooperates with c-Myc to accelerate tumor 
development in a mouse model of B-celllymphoma (120). This cluster, as well as the 
paralogous cluster miR-106a-92 induced by N-Myc, promotes cell cycle progression in 
neuroblastoma cells (175). Both c-Myc and MYCN also induce miR-9, a miRNA that 
targets CDH1, encoding E-cadherin, leading to increased cell motility and invasiveness, 
as well as increased tumor angiogenesis (80). c-Myc participates in the tumor-associated 
repression of miRNAs by directly repressing several miRNA clusters such as miR-15a-
16-1, miR-22, miR-23a/b, miR-26, miR-29 and severallet-7 clusters (176). Many of 
these miRNAs down-regulated by c-Myc are known tumor suppressors and target critical 
cell cycle regulators (177, 178). Although most of these miRNAs are down-regulated 
through the transcriptional repressor activity of c-Myc, c-Myc may also lead to miRNA 
down-regulation by alternative mechanisms. For example, c-Myc is able to block the 
maturation of specific miRNAs by inducing the RNA binding proteins Lin28 and Lin28b 
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(176, 179), which are known to act as negative regulators of let-7 maturation at multiple 
levels including Drosha and Dicer processing (180). Repression of multiple miRNAs by 
c-Myc is likely to be an important mechanism contributing to the reduced function of 
miRNAs in cancer cells (180). 
1.7. RESEARCH THEME 
Given the convergence of miRNAs and c-Myc, my dissertation studies focus on: (i) 
whether and which miRNAs target c-Myc; (ii) whether the repression of MYC by miR-
33b is sufficient to reduce medulloblastoma tumor growth; (iii) whether we can identify 
the US Food and Drug Administration (FDA)-approved drugs that induce miR-33b 
expression to inhibit c-Myc expression and function in medulloblastoma; and, (iv) 
whether epigenetic silencing of miR-33b gene is responsible for the reduced sensitivity to 
lovastatin in HeLa cells. 
First, I identified that miR-33b is a primate-specific negative regulator of c-Myc. The 
human miR-33b gene is located at 17pl1.2, a genomic locus frequently lost in 
medulloblastomas. Through a small-scale screening with drugs approved by the FDA, I 
found that lovastatin upregulated miR-33b expression, reduced cell proliferation, and 
impaired c-Myc expression and function in miR-33b-positive medulloblastoma cells. In 
addition, a low dose of lovastatin treatment at a level comparable to approved human oral 
use reduced tumor growth in mice orthotopically xenografted with cells carrying miR-
33b, but not with cells lacking miR-33b. This work presents a highly promising 
therapeutic option, using drug repurposing and a miRNA as a biomarker, against cancers 
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that over-express c-Myc. I also revealed that the promoter of the miR-33b gene is 
methylated in HeLa cells but not in medulloblastoma cells, which may contribute to the 
lower sensitivity to lovastatin of HeLa cells. This information is critical to future drug 
development against cancers other than medulloblastoma using miR-33b and c-Myc. 
32 
CHAPTER 2 
MICRORNA-33B (MIR-33B) TARGETS MYCAND NEGATIVELY AFFECTS 
MEDULLOBLASTOMA GROWTH. 
2.1. INTRODUCTION 
The MYC gene codes for the c-Myc onco-protein and is over-expressed in the majority of 
human cancers. It is now well established that the deregulated expression of c-Myc plays 
a significant role in human cancer development (181-183). The importance of c-Myc in 
carcinogenesis is supported in animal models; over-expression of Myc in mouse liver 
induces hepato-cellular carcinoma, which regresses if Myc expression is inactivated 
(184). c-Myc is a transcription factor that exert its biological functions through activating 
and repressing target genes (185, 186). Its expression is tightly control and activated 
mitogenic cues resulting in cell proliferation (183). 
Treatment of medulloblastoma remains problematic due to high doses of radiotherapy 
and chemotherapeutics that lead long-term toxicity. A major focus is the development of 
innovative approaches such as targeted therapies to reduce long-term toxicity. c-Myc is 
over-expressed in up to -31-64% of medulloblastoma (187) and has been associated with 
the large-cell/anaplastic subtype and poor survival (187). However, only -5-15% of 
medulloblastoma show an amplification of the MYC gene (188) suggesting that other 
mechanisms account for the increased c-Myc expression. Understanding how MYC is 
regulated in medulloblastoma is critical to develop targeted therapies. 
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Gene profiling and murine models have revealed that many of the pathways (Wnt, Shh, 
Myc and Notch) required in neural stem cells (NSC), multipotent cerebellar SCs and 
lineage-restricted progenitors of the EGL are also aberrantly activated in 
medulloblastoma (17, 189). Inactivation of Ptch in lineage-restricted granule cell 
progenitors and NSC has been shown to form medulloblastoma tumors (190, 191). 
Experiments in transgenic mice have revealed that expression of c-Myc is essential for 
normal developmental control of hematopoietic stem cells (HSC) and NSCs (87, 88). 
Likewise, c-Myc is crucial for self-renewal and maintenance of pluripotency in murine 
ES cells (90). Therefore, c-Myc is an attractive therapeutic target to inhibit 
medulloblastoma cell growth. miRNAs are negative regulators of gene expression and 
have been implicated in regulation of cellular processes. Myc regulates miRNA 
expression and is also regulated by miRNAs (176, 192, 193). We intend to identify 
miRNAs that target MYC as a first step toward the development of potent c-Myc 
inhibitors. 
We used a screening method, which employs a two-tiered assay to enable us to identify 
miRNAs that target MYC directly. Tier 1 is designed to identify miRNAs that function in 
a particular pathway and tier 2 is designed to determine which miRNAs targets a specific 
3'UTR. We found that miR-33b adversely regulates c-Myc through direct binding to the 
3' UTR of the MYC gene. Real-Time PCR data suggests that over-expression of miR-33b 
results in decreased levels of MYC mRNA. Also, miR-33b over-expression leads to 
down-regulation of c-Myc protein expression, and reduces c-Myc-mediated cellular 
proliferation, cell cycle progression, colony formation and cell migration. Furthermore, 
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miR-33b expression in D283-Med (D283) cells reduces neurosphere formation. 
Orthotopic injection of mice with miR-33b-expressing D283 resulted in decreased in vivo 
tumorigenesis. These results demonstrate that miR-33b is able to inhibit cell proliferation, 
cell cycle progression and suppress medulloblastoma tumor growth. 
2.2. MATERIALS AND METHODS 
2.2.1. Cell culture 
HEK293T cells were purchased from ATCC and cultured in Dulbecco's modified 
eagle's medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% heat 
inactivated fetal bovine serum (FBS) and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro, 
Manassas, VA). Rat fibroblasts Ratlc-Myc-I- (clone HOI5.19), (from Dr. Claycomb's 
Lab, Brown University) were maintained in DMEM (Gibco, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA) and 0.1 % (v/v) Antibiotic-
Antimycotic (Cellgro, Manassas, VA). Medulloblastoma cell lines, D283 and DAOY, 
were purchased from ATCC and cultured in EMEM (Gibco, Carlsbad, CA) supplemented 
with 10% FBS and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro, Manassas, VA). For 
neurosphere formation, D283 cells were cultured in neurobasal media supplemented with 
10% FBS (Gibco, Carlsbad, CA), 0.1 % (v/v) antibiotic-Antimycotic (Cellgro Manassas, 
V A), 2 mM L-glutamine, N2 supplement, B27 supplement, 20 ng/ml hrEGF, 20 ng/ml 
hrbFGF and 50 J.lg/ml BSA (Invitrogen, Carlsbad, CA). All cell lines were cultured at 
37°C in an atmosphere containing 5% CO2• 
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Transient transfection was performed using Lipofectamine LTX (Invitrogen, Carlsbad, 
CA). Transient transfection efficiency for 293T cells was >90% as judged by a control 
vector, pSIF, expressing green fluorescent protein (GFP). Efficiency for other cells lines 
was determined based on the expression of GFP from the parental pSIF vector and was 
recorded to be between 60-90%. For miRNAs, we used the parental vector pSIF as a 
vector control. For inhibitor of miR-33b, we used Anti-miR TM miRNA inhibitor (Ambion 
Inc, Austin, TX), which is chemically modified, single stranded antisense RNA to 
miRNA designed to specifically bind and inhibit the endogenous miR33b molecules. The 
negative control (Ambion, Inc., Austin, TX) used for the inhibitor is a random-sequence 
RNA molecule that has been extensively tested in many human cell lines and tissues and 
validated to not produce any identifiable effect on known miRNA function. 
Stable transfection was performed using viruses generated in 293T cells. For lentivirus 
production, 293T cells was transiently co-transfected, 24hrs post plating in 6-well plates, 
with 2f.1g of pSIF vector, or miRNA, 1.4f.1g of pVGV-S and 0.7f.1g of pFIV-34N packing 
and expression vectors respectively using Lipofectamine LTX. For retrovirus production, 
293T cells in 6-well plates were transfected with 2f.1g pCL-Eco and the vector of interest 
(pMX-EGFP as control and pMX-gene X for experiments). The lentivirus-containing or 
retrovirus containing media was collected after 48 hrs. The viral media was supplemented 
with polybrene (final concentration 5-8f.1g/ml), a polycation that neutralizes charge 
interaction to increase binding of the virus capsid to the cellular membrane, and used to 
infect desired cells. The media was changed after 12-24 hrs to minimize the toxic effect 
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of polybrene on cell viability. The efficiency of stable transfection was determined based 
on expression of GFP or RFP by fluorescent microscopy. 
2.2.2. Cloning 
MYC 3'UTR primers were designed using the Vector NTI software: forward primer 5'-
ATTCTAGAGGAAAAGTAAGGAAAACGATTCCT-3' and reverse primer 5'-
TAGCGGCCGCGGCTCAA TGATATATTTG-3'. The MYC 3' UTR primers were 
modified at both ends to carry Notl and XbaI sites. The primer set was used to amplify 
the 3 'UTR of MYC by PCR in a mixture of 0.5 ~l of 100~M of each primer, 25 ~l of 2x 
buffer H, 2.5 ~l ofTaq polymerase (Promega, Madison, WI), 0.5 ~l of lOmM dNTPs 
(Promega, Madison, WI) and 100 nM of A459 genomic DNA template. The amplified 
3'UTR (467bp) was purified from a 1 % agarose gel using Ultrafree-DA columns 
(Millipore Inc., Billerica, MA) and cloned into pGEM-T vector (Promega, Madison, WI). 
The resultant pGEM-T -MYC 3' UTR WT was digested with NotIlXbaI (New England 
BioLabs, Ipswich, MA) and cloned into the Notl and Xbal site of pRL-TK vector. 
The following primer set: reverse 5' GGC AGT TTA AGC CAT GGC TAA 3'; forward 
primer 5' -ATTCTAGAGGAAAAGT AAGGAAAACGATTCCT -3'; mutant primer 
5'GGCAGTTTAAGCCATGGCTAA3'; was used to clone the full mutantMYC 3'UTR, 
mutated at the miR-33 'seed' binding site, into the XbalINotl sites of pRL-Tk vector in 2 
PCR runs. In the first PCR the WT forward primer and the mutant primer were used to 
amplify an approximately 150bp product. The first PCR product was used as a forward 
primer for the second PCR, with the WT reverse primer to amplify the full length mutant 
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MYC 3' UTR. The product was purified using the Ultrafree-DA column (Millipore Inc., 
Billerica, MA) and cloned into pGEM-T vector (Promega, Madison, WI). This resultant 
pGEM-T-MYC 3'UTR mutant was cut with Notl and XbaI and cloned into the 
NotllXbaI site of pRL-TK vector. Likewise, the following primer set: reverse 5' GGC 
AGT TTA AGC CAT GGC TAA 3'; forward primer 5'-
ATTCTAGAGGAAAAGTAAGGAAAACGATTCCT-3'; mutant forward primer 5' 
GTACCTAAGCGGCTAGGTACTA 3' was used to clone mutantMYC 3'UTR mutated 
at the miR-369-5p 'seed' binding site into the XbalINotl site of pRL-TK. 
The oligonucleotides listed in Table 1 were used to clone the miR-33b mutant construct. 
The oligonucleotides were phosphorylated in a mixture containing 5 J11 of lOJ1M of each 
oligonucleotide (except for 1 and 9), IX of T4 polynucleotide kinase (PNK) buffer,O.5J11 
of T4 PNK (New England BioLabs, Ipswich, MA), and of IJ1M ATP at 3TC for 
30minutes. PNK was inactivated by incubating at 65°C for 5 minutes. The 
oligonucleotide was then annealed by heating at 90°C for 5 mins and eventual cooling to 
room temperature. The annealed product was adenylated by incubating with dA TP at 
72°C for 30mins. The resultant pGEM-T-miR-33b mutant construct, as well as pSIF 
vector, were digested with MfeI and BamHI and the desired bands, 150bp and 7kb 
respectively, purified with the Ultrafree-DA column (Millipore Inc., Billerica, MA). The 
mutant miR-33b insert was then ligated into pSIF at a ratio of 3:1 and confirmed based on 
band sizes following MfellBamHI restriction enzyme digest. 
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Number Oligonucleotide 
1 5' -GGATCCGTGGCGGGTGTGGGGGCCGA-3' 
2 5' -GGGGCCGCCCGCCTCTCGGCCCCCACACCCGCCACGGCTC-3' 
3 5' -GAGAGGCGGGCGGCCCCGCGGT-3 




6 5' -CCGGCTCCGGGCTGCACTGCCGAGGCACTGCACCCGCC-3' 
7 5' -GCAGTGCAGCCCGGAGCCGGCCCCTGGCACCACGG-3' 
8 5' -CAATTGAGGATGGGGGCCCGTGGTGCCAGGGG-3' 
9 5' -GTT AACTCCTACCCCCG-3' 
Table 1: Oligonucleotide for miR-33b mutant cloning 
The pcDNA3-MYC construct was purchased from Addgene (Cambridge, MA). This 
construct lacks the MYC 3'UTR but carries the MYC coding region. We then cloned 
constructs that either carried the MYC wild-type or mutant 3'UTR. pRL-TK-MYC 3'UTR, 
pRL-TK-MYC 3'UTR mutant and pcDNA3-MYC constructs were digested with HindlII 
and Xbal to generate desired bands of -500bp (pRL-TK-MYC 3'UTR, pRL-TK-MYC 
3' UTR mutant) and 5kb (pcDNA3-MYC ). The ligation experiment was set at 1:3 (insert 
to backbone construct) to generate the final pcDNA3-MYC 3'-UTR (MYC 3'UTR) WT 
and MYC 3' -UTR mutant constructs. 
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All constructs were confirmed by DNA sequencing. 
2.2.3. Luciferase assay 
E2 promoter binding factor (E2F) was originally identified as a cellular transcription 
factor which could bind to and activate the adenovirus E2 promoter (194). E2F activity 
appears to playa critical role in cell growth regulation through the activation of a variety 
of genes that encode proteins important for DNA replication in S-phase, as well as 
various genes that encode cell cycle regulatory proteins that facilitate the transition 
through the cell cycle (195, 196). The E2F2 promoter has 4 distinct E-boxes to which c-
Myc can bind to regulate E2F2 protein expression (197). pSIF, the parental vector for all 
our miRNA constructs, served as the control. Renilla luciferase (Rluc) from pRL-TK for 
tier-1 and luciferase (Luc) reporters from the pGL3-Promoter for tier-2, are used to 
normalize transfection efficiency and total protein synthesis. If a miRNA directly targets 
the MYC gene, both LuclRluc of the tier-1 assay and Rluc/luc of the tier-2 assay will be 
down-regulated compared to respective controls. However, if a miRNA indirectly down-
regulates c-Myc, only LuclRluc expression in the tier-1 assay is likely to be reduced. The 
success of this strategy depends on: (i) a cell line with a proven record in a specific 
pathway; (ii) endogenous miRNA expression levels may dictate how many fold the 
exogenous construct can over-produce a specific miRNA, which can be addressed by 
comparing levels in cells with or without the miRNA construct, or using antisense to 
miRNA to inhibit endogenous expression. 
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We used a two-tier screening assay: tier-l is designed to identify any miRNA that 
modulates the c-Myc signaling pathway, and tier-2 is designed to determine which 
miRNAs binds the MYC 3 'UTR. In tier-I, we made use of an E2F2-Luciferase construct 
(E2F2-Luc). This construct is made up of a luciferase gene whose expression is regulated 
by the E2F2 promoter cloned down-stream of the luciferase gene. In this case miRNA 
modulation of endogenous c-Myc activity regulates firefly luciferase activity. The given 
miRNA can target c-Myc expression by either binding the 3'UTR of MYC or the 3'UTR 
of other genes that regulate c-Myc expression. Based on endogenous c-Myc expression, 
differential binding to the E2F2 E-box occurs, and this is determined based on the 
luciferase reporter measurement. The pRL-TK (renilla luciferase -Rluc) expression 
vector is used as an internal control. HEK293T cells (3 x 104 cells/well) were co-
transfected in triplicate wells with 80 ng/well of pSIF, or -400 miRNA present in our 
miRNA library, 20 ng/well of pRL-TK and 100 ng/well of the E2F2-Luc construct using 
the Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA). Luciferase reporter activity 
was measured 48 hrs post-transfection using the Dual-Glo Luciferase assay system 
(Promega, Madison, WI) as per the manufacturer's instruction. To determine the effect of 
a specific miRNA on the c-Myc pathway, the ratio of LuclRluc was calculated. The value 
from the vector-transfected wells was normalized to a value of one, and the values from 
cells transfected with miRNAs were analyzed in comparison to this. Values lower than 
one indicated a negative effect on the c-Myc pathway. Similarly, the Dual Glo Luciferase 
assay was used to determine whether mutation of the E2F2 WT construct abrogated the 
effects of miRNA targeting. The E2F2-luc mutant construct has mutated bases in two of 
the E2F2 promoter E-boxes. These mutations have been shown to significantly affect c-
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Myc activity on the E2F2 promoter resulting in reduced luciferase reporter activity (197). 
This mutant construct (lOOng/well) was co-transfected with 80 ng/well of miR-33b, miR-
33a or pSIF, and 20 ng/well ofpRL-TK vector into 293T cells (3 x 104cells/well) in 96-
well plates. Dual Glo luciferase assay was performed 48 hrs later. Analysis was 
performed as described for the wild type E2F2-luc construct assay. 
Tier-2 assay was designed to determine miRNAs that directly bind the 3'UTR of target 
genes. In this assay, we used a cloned pRL-TK-MYC 3'UTR-Luc construct and a pGL3-
Luc construct as a transfection control. In this system, binding of miRNA to the 3' UTR 
mediates the down-regulation of Rluc expression. We co-transfected 293T cells (3 x 104 
cells/well) in 96-well plates with 120 ng/well ofpRL-TK-MYC-3'-UTR WT, 80 ng/well 
of 56 miRNAs (individually) predicted from TargetScan and Miranda to target MYC, and 
20 ng/well of pGL3-Luc construct (which act as intemalluciferase control) in triplicate 
wells. Dual-Glo Luciferase assay (Promega, Madison, WI) was performed and miRNAs 
binding the MYC 3'UTR were determined based on LuclRluc ratio. The value obtained 
from vector-transfected wells were normalized to one and the values for the miRNAs 
were analyzed in comparison to this, with values lower than one indicating binding to 
MYC 3'UTR and negative regulation of MYC. A pRL-TK-MYC-3'UTR mutant construct, 
mutated at 4 nucleotides that form complementary base pairs with the miR-33b seed 
region, was used to determine whether preventing miR-33b binding at the seed region 
will abrogate down-regulation of the luciferase reporter. 293T cells (3 x 104 cells/well) in 
96-well plates were co-transfected with 120 ng/well of pRL-TK-MYC 3'UTR mutant, 80 
ng/well of miR-33b and 20 ng/well of pGL3-Luc construct (intemalluciferase control) in 
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triplicate wells, and Dual-Glo Luciferase assay was performed. The data were analyzed 
similarly to that of the WT construct. 
2.2.4. Western blot analysis 
HEK293T cells (lx106cells/well) cultured in 6-well plates were transfected with 2.5 Ilg 
of pSIF, miR-33b, and miR-33a or miR-333b mutant. Medulloblastoma cell lines -
DAOY and D283-Med were stably transfected with pSIF-mKate or miR-33b. Total 
protein was extracted using IX RIPA reagent (Cell Signaling Technology, Danvers, MA) 
containing IX protease inhibitor cocktail (Sigma, St. Louis, MO). The protein 
concentration was determined using the Bicinchoninic Acid (BCA) method (Thermo 
scientific, Rockford, IL) according to the manufacturer's protocol. The sample was boiled 
with Leammli buffer for 10 mins, fractionated by SDS-polyacrylamide gel 
electrophoresis and transferred at 4°C to nitrocellulose membranes. Protein membranes 
were incubated in blocking buffer (Ix Tris-buffered saline - TBS, ph 7.5,5% Non-fat 
dried milk) for 2 hrs at room temperature. The membranes were incubated over-night at 
4°C on a shaker with anti-c-Myc (Santa Cruz, Santa Cruz, CA; sc-40; diluted 1:1000), 
anti-Cyc1in E (Santa Cruz, Santa Cruz, CA, ; sc-25303; diluted 1:1000), anti-VEGF-A 
(Santa Cruz, Santa Cruz, CA; sc-7269; diluted 1: 1000), anti-Gadd45 (Santa Cruz, Santa 
Cruz, CA; sc-6850; diluted 1:1000), anti-ODC (Cell signaling, Danvers, MA: 1:1000) or 
~-Actin (Sigma, St. Louis, MO; AC-15; diluted 1:5000) antibodies. The membranes were 
washed 3 times, 10 minutes per wash, with Ix TBS containing 0.05% Tween 20, 
incubated with horse peroxidase-linked goat anti-mouse IG antibody (Santa Cruz, Santa 
Cruz, CA; sc-2005; 1:5000) or goat anti-rabbit IG antibody (Cell Signaling, Danvers, 
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MA) for 1 hr at room temperature, washed 3X for 10 mins, and visualized with the 
Supersignal west DuralFemto Chemiluminescent substrate kit (Pierce, Rockford, IL). 
c-Myc null cells, H015.19 (2x106 cells/ well) were plated in 6-well plates and co-
transfected with 2 ~g pSIF, miR-33b or miR-33a, and 2~g ofpcDNA3.1-MYC-MYC 3'-
UTR or pcDNA3.1-MYC-MYC 3'-UTR mutant. Total protein was extracted 48 hrs after 
transfection and western blot analysis performed to determine c-Myc, and Cyclin E and 
~-Actin expression. 
The quantification of protein expression levels was determined by ImageJ 
(http://rsb.info.nih.gov/iD with arbitrary units (AU) reflecting the signal density from the 
blot. 
2.2.5. Quantitative real-Time PCR (qRT-PCR) 
TaqMan miRNA assay and gene expression assay (applied Biosystem inc., Forest City, 
CA) were used to detect the expression level of mature miRNAs and gene mRNA 
expression, respectively (198). U6 RNA and fl-Actin mRNA was used for normalization. 
To determine whether miR-33b affects MYC mRNA levels, 293T cells (5x104cells/well), 
were plated in 12-well plates and transfected with l~g of pSIF, miR-33b, miRNA 
inhibitor negative control or antisense miR-33b. Also, D283 and DAOY cells were stably 
infected with empty vector or miR-33b. Total RNA was extracted 48 hrs post-
transfection by one of two methods: the cells were washed twice with IX PBS, 
resuspended in 50 ~l of IX PBS and heated at 95°C for 5 mins; or total RNA was 
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extracted using TriZol reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's 
protocol. Total RNA concentration was detected by nanodrop. To quantify miR-33b 
expression levels, reverse transcription (RT) reaction was performed with 100 ng RNA in 
a reaction mixture containing 5x miR-33b and U6 RT primer, IX RT buffer and 
0.0125mM DTT. For mRNA expression level, reverse transcription (RT) reaction was 
performed with 100 ng RNA using the iScript cDNA synthesis Kit (Bio-RAD, Hercules, 
CA) as per the manufacturer's instruction. Reverse transcription conditions were as 
follows: 16°C for 30 mins, 42°C for 30 mins and 85°C for 5 mins. The PCR product was 
used in a TaqMan PCR miRNA or gene expression assay (ABI, Forest City, CA). 
TaqMan 20x probe for miR-33b was used to detect expression levels of miR-33b and 
TaqMan 20x probe for MYC was used to detect expression levels of MYC mRNA. U6 
RNA or ~-Actin mRNA was used for normalization. Similar experiments were done with 
total RNA extracted from MYC null cells H015.l9, co-transfected with; lllg of pSIF, 
miR-33b or miR-33a and lllg ofpcDNA-MYC-MYC 3'-UTR WT or pcDNA-MYC-MYC 
3' -UTR mutant. 
To determine the expression level of stem cell marker genes, TaqMan gene expression 
assay was performed from total RNA extracted from neurospheres and differentiated 
neurospheres. D283 cells, stably transfected with vector or miR-33b and cultured in 
neurobasal media, formed neurospheres that were further differentiated by culturing in 
EMEM growth media. Total RNA was extracted from neurospheres or differentiated 
neurospheres using TriZol reagent. cDNA was synthesized using the iScript kit and used 
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for TaqMan real-time PCR for MELK, MYC, SOX2, CD133 andfJ-Actin mRNA 
quantification. 
To determine whether c-Myc activates the miR-33b promoter, 293T cells and HeLa cells 
(1 x 104 cells/well) were plated in 24-well plates and transfected with 3 ~g of 
pcDNA3.1+, or 1,2, or 3 ~g ofpcDNA-MYC, and total RNA extracted after 48hrs. QRT-
PCR was performed using the TaqMan gene or miRNA expression assay for 
quantification of MYC mRNA and miR-33b levels. fJ-Actin and U6 were used as internal 
controls. 
2.2.6. Cell cycle analysis 
D283 and Daoy cells were stably transfected with empty vector or miR-33b. Also, Myc 
null cells, H015.19, were co-transfected with vector or miR-33b and pcDNA-MYC 
3'UTR or pcDNA-MYC 3'UTR Mut. The various cell types were collected after 48 hrs 
and washed twice in IX PBS. Cells were suspended in 1ml of ice-cold 70% ethanol and 
kept at 4°C for 24 hrs. The next day, the cells were washed twice with IX PBS and 
treated with 1mglml Ribonuclease for 90 mins at 3TC in 0.5 ml of IX PBS. Before cell 
cycle analysis, cells were stained with 5~glml of PI and protected from light. Flow 
cytometry was performed with a F ACScan apparatus. A minimum of 20,000 cells per 
sample were collected and the FACS files were further analyzed using FlowJo software 
(Tree Star Inc., Ashland, OR) for cell cycle analysis. The excitation wavelength was 
488nm, and red fluorescence (>590 nm for PI) was recorded. In addition, the parameters 
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for forward scatter (FSC) and side scatter (SSC) were determined. For each variable 
(exposure condition, culture period etc.) a minimum of 3 samples were quantified. 
2.2.7. Transwell cell migration assay 
D283 (lx104 cells/well) and Daoy (lx104 cells/well) cells were stably transfected with 
1.6 I1g of empty vector or miR-33b, washed twice with IX PBS and resuspended in 
serum-free EMEM. Transwell (Boyden) assay was then performed 48 hrs after 
transfection. Briefly, Transwell (Boyden) chambers (Invitrogen, Carlsbad, CA), with a 
pore size of 811m, were placed into triplicate I2-well plates. EMEM media supplemented 
with IO% FBS which served as a chemoattractant was added to wells beneath the 
Transwell chamber. D283 cells (lx104) or Daoy cells (lxlO\ in 0.5ml of serum-free 
EMEM media were added to the Transwell chamber and the plates were then incubated at 
3TC in a humidified 5% CO2 atmosphere for 24 hrs. The cells were fixed with methanol 
for 10 mins, and stained with 0.4% crystal violet for 2 hrs. Non-migrated cells on the 
upper side of the filter were removed with a cotton swab, and the filter mounted on 
microscope glass slides. Images were captured using a Nikon Eclipse TE300 microscope 
and a Nikon Plan Fluor lOx0.30 objective. The migrated cells were counted using ImageJ 
software. D283 and Daoy cells (0.5x104) similarly transfected, were cultured in serum 
free media, and 24hrs later MTT cell proliferation assay performed. 
2.2.8. Neurosphere assay 
The neurosphere assay has proven to be an excellent technique to isolate neural stem cells 
and progenitor cells to investigate the differentiation and potential of cell lineages. 
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Medulloblastoma is believed to have a stern cell origin; therefore we reasoned that 
growth of medulloblastoma cells in media that favors neural stern cell growth will result 
in neurosphere formation. D283 cells (1 x 106) were stably transfected with empty vector 
or miR-33b and neurosphere assay performed. Briefly, the cells were trypsinized, 
washed in neurobasal medium (Invitrogen, Carlsbad, CA) and resuspended in Matrigel-
coated plates at 5x104 cells/ml in the neurobasal medium containing 2rnM L-glutamine, 
N2 supplement, B27 supplement, 20ng/ml hrEGF, 20ng/ml hrbFGF and 50)lg/ml BSA 
(Invitrogen, Carlsbad, CA). The growth factors, 20ng/ml hrEGF and 20ng/ml hrbFGF, 
were added daily to the plates and the neurobasal medium were replaced twice per week 
with fresh neurobasal media. After lOdays of incubation, primary neurospheres were 
disaggregated into single-cell suspensions and reseeded to form secondary, tertiary and 
quaternary spheres in 96-well plates. Spheres larger than 50)lm in diameter were counted 
by microscopy (magnification, lOX) and quantified. 
2.2.9. Soft agar colony formation (clonogenic) assay 
Clonogenic assay or colony formation assay is an In Vitro cell survival assay based on 
the ability of a single cell to grow into a colony. The assay essentially tests every cell in 
the population for its ability to undergo "unlimited" division. The effect of miR-33b over-
expression on colony formation ability of D283 cells was assessed by soft agar colony 
formation assay. Medulloblastoma D283 cells were stably transfected with empty vector 
or miR-33b. The cells were collected in fresh EMEM media after 48hrs and incubated in 
soft-agar. The soft agar plate contains a bottom layer of 0.5% agar and a top layer of 
0.2% agar. Approximately 2000, appropriately transfected, D283 cells were plated over 
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the top layer of a 6-well plate. The cells were maintained at 3TC in a humidified 5% CO2 
atmosphere for two weeks. Fresh media was added at regular intervals to prevent the 
plates from drying out. At the end of two weeks, the cells were treated with 0.5% of MTT 
reagent for 2-3 hrs. Colony sizes were assessed after imaging using a scanner or 
microscopy (original magnification, x4). 
2.2.10. Orthotopic tumor formation 
All animal experiments were conducted according to a protocol approved by the 
University of Louisville Animal Care and Use Committee (IACUC number 08107). D283 
cells (1 x 106cells/well) in 6 well plates were stably transfected with vector or miR-33b. 
Positive transfection was checked by visualization of red fluorescent protein (RFP) 
expressed by the vector and, positive transfectant were selected with 400f..lglml of G418 
(Cellgro). Recipient immunodeficient nude mice were purchased from Taconic (C.B-Igh-
1 b /IcrTac-Prkdcscid; FOX CHASE CB-17 SCID ICR; Taconic). Male 9- to 12-week old 
mice were anesthetized with rapid-sequence inhalation isofluorane (Abbot Laboratories, 
Abbott Park, IL). lO-mm skin incision was made along the midline of the head and a 
1mm burr-hole was drilled into the skull and a total of 1x105 cells expressing the empty 
vector or miR-33b were orthotopically injected into the cerebellum of each 
immunodeficient nude mouse. The mice were monitored for any sign of distress and 
maintained for 6 weeks in the animal housing facility at the University of Louisville. The 
mice were sacrificed 6 weeks later and fixed in 10% formalin for 3 days. After fixation, 
the brains were embedded in paraffin and 5 f..lm thick sections were made following 
routine procedure. 
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H&E staining was performed to determine size and location of tumors formed by D283 
cells either expressing empty vector or miR-33b. Briefly, the tissue sections were 
deparafinized by incubating twice in xylene for 10 mins per incubation. The sections 
were then rehydrated by incubating twice for 5 mins in 100% ethanol, then for 2 mins 
each in 95% and 70% ethanol. The section was then washed with copious amounts of 
distilled water and stained by incubating in Harris hematoxylin (Sigma, St. Louis, MO) 
solution for 10 mins, followed by washing with tap water for at least 5 mins. The sections 
were then differentiated by incubating in 1 % ethanol for 30 seconds and washed with tap 
water for 2 mins. The sections were then washed and rinsed in 90% ethanol and counter-
stained in eosin-phloxine (Sigma, St. Louis, MO) solution for 0.5-1 min. After the 
staining the section were dehydrated by incubating twice in 95% ethanol for 5 mins per 
incubation and 2 changes of xylene for 5 min per change. The sections, from comparison 
brain location, were then mounted on the microscope using xylene based mounting 
medium. Images of the tumors or whole brain were taken using a microscope 
(magnification 20X, 100X, 200X and 400X). Tumor surface area was determined using 
the Olympus microscope. 
2.2.11. Immunohistochemistry (IHC) 
Immunohistochemistry was performed according to the avidin biotin complex (ABC) 
peroxidase method using Rabbit and Mouse IgG ABC Elite1 detection kits (Vector 
Laboratories, Burlingame, CA). Prior to the performance of the immunohistochemical 
procedure, 5 !lm thick histological sections from paraffin-embedded tissue blocks were 
subjected to non-enzymatic antigen unmasking in 0.01M sodium citrate buffer (pH 6.0) 
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for 10 min in a microwave at medium power. The rabbit polyclonal antibody against c-
Myc (Santa Cruz; SC-789; Dilution 1 :500), rabbit monoclonal antibody against Sox2 
(Cell signaling; D6D9; Dilution 1:500), rabbit monoclonal antibody PC 10 to PCNA (Cell 
Signaling; PClO: Dilution 1:100), and rabbit monoclonal antibody against Cyclin E 
(Abcam; ab7959: Dilution 1: 100) were used to determine protein expression. Briefly, 
tumor sections on slides were deparaffinized by incubating in HD 1 and HD2 solution for 
10 mins per solution. This was followed by re-hydration by incubating at: 100%, 95%, 
80%, and 70% ethanol for 5 mins per solution, followed by 5 min incubation in lXPBS. 
The slides were then washed copiously with dH20. The tumor sections were incubated 
with a proteinase K for 5 mins and peroxidase block solution for 15 mins at room 
temperature. Primary antibody against c-Myc, Sox2 or PCNA was added and the slides 
were incubated overnight at 4°C. The slides were then washed three times with IX PBS 
and incubated with secondary anti-rabbit-HRP antibody for 1.5 hrs. The slides were then 
washed three times with IX PBS at 10 mins per wash. This was followed by chemical 
reaction of the horse radish peroxidase (HRP) attached to secondary antibody by 
incubating tissue sections in HRP DAB substrate buffer, followed by counter staining 
with methyl green or hematoxylin solution. The slides were then washed in dH20. The 
tumor samples were then dehydrated by incubation for 5 mins each in 70%,80%,95% 
and 100% ethanol and the HD 1 and 2 solutions for 10 mins each. Tumor slides were 
imaged by microscopy (magnification, 20X, 40X, 100X, 200X and 400X). The tumor 
images were scored on a scale of 0 to 3 (3 indicating strong expression, 2 moderate 
expression, 1 medium expression, 0 no expression) by three independent scorers. 
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2.2.12. Statistics 
The experimental results were expressed as the mean ± standard deviation of at least 3 
independent experiments. Two-tail Student's t-test was performed with p:SO.05 (*) 
considered as statistically significant between the samples and their respective controls. 
2.3. RESULTS 
2.3.1. MicroRNAs targetMYC 3'-UTR 
We used reporter assays to screen miRNAs for their ability to modulate c-Myc 
transcriptional function and target MYC 3'UTR directly (Fig. 3). In Assay 1, a firefly 
luciferase gene (luc) is driven by the promoter to E2F2 (E2F2-luc), which is regulated by 
c-Myc (197). miRNAs-of-interest, E2F2-luc, and a Renilla luciferase (Rluc) construct 
constitutively expressing Rluc are co-introduced into 293T cells to screen miRNAs that 
down-regulate the reporter luc. In Assay 2, we cloned the 3'UTR of MYC downstream of 
the Rluc construct and co-expressed it with a respective miRNA and a constitutively 
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Fig. 3: The 2 tier luciferase screening method. (A) Assay 1 is designed to identify 
miRNA that functions in the c-Myc pathway and can either target the 3 'UTR of 
MYC or the 3 'UTR of another gene that regulate c-Myc activity. (B) Assay 2 is 
designed to identify miRNAs that directly target the 3 'UTR of MYC. The MYC 
3 'UTR ofMyc is cloned down-stream of a renila (Rluc) gene and binding of the 
miRNA to the 3 'UTR down-regulates the luciferase activity from RIuc. 
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We performed Assay 1 in 293T cells using hundreds of miRNA minigenes in our genetic 
library (199) and found that 4 miRNAs (miR-33a, miR-33b, miR-212, miR-203) 
significantly down-regulated the c-Myc-dependent reporter, while miR-21O up-regulated 
it (Fig. 4A). Next, we performed Assay 2 using 54 miRNAs that were predicted to target 
MYC and found that miR-33b and miR-203 down-regulated the reporter with MYC 
3'UTR downstream (Fig. 4B). Our results with miR-21O suggested that it did not target 
the 3'UTR of MYC, but up-regulated c-Myc-dependent luc expression, which is 
consistent with a recent study demonstrating that miR-21O targets MNT, an antagonist of 
c-Myc (200). To determine whether MYC is a bonafide miR-33b target gene, we 
performed Assay 1 using a mutant E2F2-luc construct, in which 2 of its 4 E-boxes (c-
Myc binding sites) were disrupted (197). As expected, the expression of luc was 
significantly reduced (-10 fold) when E-boxes on the promoter were perturbed (Fig. 5A). 
The regulation of luc by miR-33b was abolished with the removal of 2 E-boxes (Fig. 5A). 
When a MYC 3'UTR mutation construct (Fig. 5B) that disrupts miR-33b binding to the 
'seed' sequence of miR-33b was used in Assay 2, we found that the down-regulation of 
Rluc by miR-33b was abrogated (Fig. 5B). Our results verified that miR-33b is a 
negative regulator of c-Myc through directly targeting MYC 3'UTR. 
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Fig.4: miR-33b is a negative regulator of c-Myc directly targeting the MYC 
3'UTR. (A) Luciferase assay from an E2F2-luciferase construct. The Luciferase 
activity is under the control of the E2F2 promoter that contains 4 c-Myc binding 
E-boxes. Values below the RLU ofthe vector (normalized to 1) indicate down-
regulation of luciferase activity. (B) RIuc assay from a Myc 3 'UTR cloned 
upstream of the renilla luciferase gene. Values below the RLU of the vector 







MYC3'UTR 5' -CAAAUGCAUGAUCAAAUGCAAC - 3 I 
IIIIII IIIIII 
miR·33b 3' -CGUUACGUUGUCG-UUACGUG- 5 I 
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MYC3'UTR Mut 5 I -CAAAUGCAUGAUCACCGACAAC - 3 I 
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Vector Vector miR·33b 
Fig.5: Mutant E2F -luc or MYC 3 'UTR are not targeted by miR-33b. (A) Luciferase 
assay from E2F2-Luciferase mutant construct. Two c-Myc binding E-Boxes are 
mutated. (B) Luciferase assay from a MYC 3'UTR mutant construct (Right). 
Mutant construct containing four nuc1eotides substitution at the miR-33b ' seed' 
binding site on MYC 3 'UTR (Left). 
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2.3.2. Over-expression of miR-33b in 293T, Daoy and D283 cells down-regulates 
MYC mRNA expression 
We used TaqMan miRNA and gene expression assays to determine which possibility is 
favored by miR-33b on MYC mRNA. In the scenario where a miRNA leads to mRNA 
translational repression, the steady state level of mRNA in the cell will remain unchanged 
despite down-regulation of protein expression, whereas if the miRNA leads to cleavage 
of the mRNA, down-regulation of the target gene's mRNA will be observed. Following 
transfection of miR-33b into 293T, D283 and Daoy cells, total RNA was extracted and 
used for TaqMan qRT-PCR. The miR-33b expression was increased by more than 10 fold 
following over-expression compared to the parental vector control. The steady state 
levels of MYC mRNA were significantly reduced with miR-33b over-expression in 293T 
(Fig. 6A), D283 (Fig. 6B) and Daoy cells (Fig. 6C), suggesting that mRNA degradation 
likely contributed to miR-33b-mediated MYC suppression. 
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Fig.6: Over-expression of miR-33b results in decreased levels of MYC mRNA. (A) 
QRT -PCR shows that MYC mRNA levels are reduced following transient 
transfection of miR-33b for 48 hrs. (B) Stable transfection of miR-33b in miR-
33b-negative medulloblastoma cells results in decreased levels of MYC mRNA by 
qRT-PCR. (B) QRT-PCR of MYC mRNA level is reduced in response to over-
expression of miR-33b in miR-33b-positive Daoy cells. 
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2.3.3. miR-33b down-regulates the expression of c-Myc protein and its 
transactivational function in 293T cells 
To determine whether miR-33b expression result in down-regulation of c-Myc protein 
expression, we over-expressed miR-33b and performed western blot analysis. We 
transfected increasing amounts of miR-33b expression constructs (0, 1,2 and 3 Ilg) into 
293T cells in 6-well plates and found that over-expression of miR-33b down-regulated c-
Myc protein levels in a concentration-dependent manner (Fig. 7 A). We did not pursue 
miR-203 as it did not reduce c-Myc protein levels (Fig. 7 A). In subsequent experiments, 
except when stated, we use 2 Ilg of miR-33b expression plasmid to avoid a significant 
reduction of cell proliferation and unwanted cell death. We noted that miR-33b but not 
miR-33a down-regulated c-Myc expression (Fig. 4B), although miR-33a differs from 
miR-33b by only two nucleotides (UA compared to CG respectively) on position 9 and 
10 of their mature sequences (Fig. 7B). We constructed a mutant miR-33b (miR-33bM) 
whose mature sequence resembled miR-33a (Fig. 7B). Over-expression of miR-33b but 
not miR-33a or miR-33bM reduced the protein levels of c-Myc, as well as two known c-
Myc transactivational targets: Cyclin E and ornithine decarboxylase (ODC); while 
Gadd45u, a c-Myc-repressed target was up-regulated (Fig. 7C). The miR-33b binding 
site is present in MYC 3 'UTRs from human, chimpanzee, and rhesus, but not those from 
mouse, rat, dog, and other mammals (Fig. 8A) and miR-33b is only present in primates 
(201), suggesting that miR-33b is a primate-specific regulator of c-Myc. Over-
expression of an exogenous MYC gene in 293T cells did not increase the expression 
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Vector miR-33b miR-33a miR-33bM 
Fig. 7: Over-expression of miR-33b in 293T cells down-regulates c-Myc and its 
target genes. (A) Western blot analysis for expression of c-Myc in 293T cells 
transfected with increasing concentration of miR-33b. miR-203 did not affect c-
Myc protein expression (B) Schematic representation of the binding of miR-33b, 
miR-33b mutant (miR-33bM) to MYC 3'UTR. (e) Western blot analysis for c-
Myc, eyclin E, ODe and Gadd45 a. levels upon over-expression of miR-33b, 
miR-33a or miR-33bM in 293T cells. 
60 
}\CGUUACGUUGUCG-UUACGUG 










































Fig. 8: c-Myc does not regulate miR-33b expression. (A) miR-33b gene exists in 
human, chimpanzee, and Rhesus, but not in other animals even though they all 
possess the host gene SREBF1. (B) QRT-PCR for MYC mRNA and miR-33b 
from 293T cells following transfection with a c-Myc expression vector, pcDNA-
MYC. The expression of miR-33b remains constant following c-Myc over-
expression. 
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2.3.4. miR-33b down-regulates exogenously expressed c-Myc in MYC-null H015.19 
cells 
To further validate that miR-33b specifically targets MYC, we introduced two c-Myc 
constructs into a MYC-null cell line H015.19 (202): both have a native c-Myc coding 
sequence but one with a wild-type 3' UTR (3' UTR WT) and the other with a mutant 
3'UTR, in which the miR-33b binding site was disrupted (3'UTR Mut). As shown in Fig. 
9A, miR-33b down-regulated the expression of c-Myc and Cyc1in E in cells with 3'UTR 
WT but not in those with 3'UTR Mut. The changes of MYC mRNA levels showed similar 
patterns to that of the protein levels (Fig. 9B). miR-33b led to more Gl arrest in cells 
carrying MYC with 3' UTR WT compared to that with 3' UTR Mut (Fig. 9C). These 
results show that miR-33b regulation of c-Myc expression and function is dependent on 
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Fig. 9: miR-33b down-regulates exogenously expressed c-Myc in MYC-null 
H015.19 cells. (A) Western blot analysis show that miR-33b down-regulates 
exogenously expressed c-Myc from a MYC construct with the 3 'UTR WT, but 
not a 3 'UTR mut, and c-Myc transcriptional target Cyclin E. (B) qRT-PCR 
demonstrates a reduction in MYC mRNA level following miR-33b over-
expression. (C) Flow cytometry analysis for cell cycle progression of MYC-null 
cells following over-expression ofmiR-33b On the left is a representative photo 
of a single flow cytometry run with the y-axis donating events (number of cells) 
and the x-axis donating the emitted fluorescent of the DNA dye (PI): the bar 
graft on the right is provided to summarize three independent runs. 
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2.3.5. Re-introduction of miR-33b in D283 cells down-regulates c-Myc and adversely 
affects its functions. 
The human miR-33b gene is located in intron 17 of SREBF1-miR-33b gene and their 
genomic locus 17p11.2 is frequently lost in medulloblastoma. c-Myc is over-expressed in 
-31-64% of medulloblastoma, yet MYC amplification only accounts for -5-15% of cases 
(96). We hypothesize that miR-33b loss is responsible for c-Myc over expression, in 
medulloblastoma. We first employed D283, a medulloblastoma cell line without 17p11.2 
with no MYC gene amplification, yet with high levels of c-Myc (203). When miR-33b 
was reintroduced, c-Myc expression was down-regulated, along with its transactivation 
targets Cyc1in E and ODC, and Gadd45a (a c-Myc repressed target) was up-regulated 
(Fig. lOA). Coinciding with down-regulation of Cyc1in E, more cells arrested at the G 1 
phase when miR-33b was over-expressed in D283 cells (Fig. lOB). The role played by c-
Myc in inducing cell proliferation and apoptosis is partly due to its ability to up-regulate 
ODC and Gadd45a expression, respectively. Over-expression of miR-33b resulted in 
reduction in MTT -assayed cell proliferation compared to empty vector alone (Fig. 11A). 
To verify whether the reduction in cell proliferation by miR-33b is dependent on MYC 
3'UTR, D283 cells were transfect with a MYC-expressing construct carrying either 
3'UTR WT or 3'UTR Mut, in which the miR-33b binding site was disrupted 
(3'UTRMut). As miR-33b targets 3'UTRWT but not 3'UTRMut, cell proliferation was 
reduced only in cells carrying MYC with the 3'UTRWT (Fig. lIB). We also found miR-
33b reintroduction down-regulated the expression of miR-9, a miRNA regulated by c-
M yc (204) that mediates cell migration (Fig. 11 C) and resulted in a reduction in cell 
migration (Fig. lID). 
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Collectively, these data support that reintroduction of miR-33b into miR-33b-null D283 
cells caused down-regulation of c-Myc and its transcriptional targets, decreased cell 










~ 50 62 (43.95"1 
> 


























Fig. 10: Re-introduction of miR-33b in D283 cells results in negatively regulates c-
Myc expression and c-Myc-mediated function. (A) Western blot analysis for 
c-Myc, Cyclin E, ODC and Gadd45a expression in D283 cells following stable 
transfection with the parental vector or miR-33b. (B) Flow cytometry analysis to 
determine cell cycle progression ofD283 cells transfected with vector or miR-
33b. On the left is a representative photo of a single flow cytometry run with the 
y-axis denoting events (the number of cells) and the x-axis denoting the emitted 
fluorescence of the DNA dye (PI); a bar graph on the right is provided to 
summarize three independent runs. 
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Fig. 11: miR-33b negatively affects c-Myc-mediated cell proliferation and migration 
of D283 cells. (A) MTT cell proliferation/viability assay of D283 cells stably 
transfected with vector or miR-33b. (B) D283 cell proliferation is rescued 
exogenous c-Myc from a MYC 3'UTR mutant construct, but not a MYC 3'UTR 
WT construct. (C) QRT-PCR for the expression of miR-9 in D283 cell stably 
transfected with vector or miR-33b. (D) Transwell cell migration assay D283 
cells. The upper panel is a representative photo of migrated cells; the bottom 
panel is the bar graph summarizing three independent experiments. 
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2.3.6. Stem cell characteristics of D28 cells are abrogated by miR·33b 
Medulloblastoma is a tumor which is characterized by an undifferentiated stem- or 
progenitor-like appearance in the majority of its cells with neurons, and glia cell types 
detected. c-Myc is a major player in the maintenance of stem cell self-renewal (88, 205) 
and appears to playa crucial role in medulloblastoma development. Medulloblastomas 
have been reported to have a stem cell origin and are capable of forming neurospheres 
when incubated in neurobasal medium (206, 207). Even in regular growth medium, there 
is a major morphological change (multicell aggregates to desegregated single cell 
suspension) in D283 cells stably transfected with miR-33b (Fig. 12A). When cultured in 
neurobasal medium, D283 cells with miR-33b formed fewer neurospheres compared to 
the control (Fig. 12B). In neurobasal medium, the mRNA levels of MYC and two stem 
cell markers SOX2 and CD133 was reduced with miR-33b overexpression, while in 
growth medium, miR-33b introduction resulted in decreased expression of SOX2 and 
MYC but not that of CD133 (Fig. 12C). We also determined the expression of a neural 
stem cell marker Musashi, a RNA-binding protein that is essential for neurosphere 
formation and proliferation(208-21O). miR-33b-expressing D283 neurospheres had 
lower levels of Musashi, while Musashi expression was not altered significantly when 
cells were cultured in growth medium (Fig. 12D). These results show that miR-33b 
expression is sufficient to activate differentiation of medulloblastoma cells via c-Myc 
down-regulation. Furthermore, miR-33b over-expression results in the negative 
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Fig. 12: Stem cell characteristics of D283 cells are adversely affected by miR-33b. 
(A) Morphological change of D283 cells with stable expression of miR-33b in 
growth medium. (B) Neurosphere formation assay of D283 cells stably 
transfected with parental vector or miR-33b. MiR-33b is impaired in neurobasal 
medium. The top panel donates a representative photo of primary and 
secondary neurospheres; the bottom panel is a bar graph summarizing three 
independent experiments (C) QRT-PCR for the mRNA levels of the stem cell 
markers MELK, MYC, Sox2 and CD133 from RNA extracted from Neurosphere 
or differentiated neurosphere. (D) Immunocytometry to determine the levels of 
musashi in stably transfected vector or miR-33b D283 neurospheres or 
differentiated neurospheres.MmiR-33b expression results in reduced expression 
of Musashi in neurospheres. 
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2.3.7. Over-expression of miR-33b in Daoy cells down-regulates c-Myc and adversely 
affects c-Myc-mediated cellular function 
We used a medulloblastoma cell line, Daoy, with intact SREBF1-miR-33b gene to 
determine whether over-expression of miR-33b will negatively affect medulloblastoma 
development. Daoy medulloblastoma cells are adherent cells and, unlike D283 cells, have 
a 'glial' phenotypic profile. Daoy are desmoblastic in origin and exhibit a less aggressive 
characteristic compared to the metastatically derived D283 cell line. Over-expression of 
miR-33b resulted in down-regulation of the protein levels of c-Myc and its targets Cyclin 
E and ODC (Fig. 13A). Gadd45u, a protein repressed by c-Myc, was up regulated (Fig. 
13A). Over-expression of miR-33b in Daoy cells resulted in delay at G 1 cell cycle (Fig. 
13B) and decreased cell proliferation (Fig. 14A). Finally, the expression of miR-9 was 
decreased (Fig. 14B) and cell migration was significantly reduced when miR-33b was 
over expressed in Daoy cells (Fig. 14C). 
These results demonstrate that miR-33b has similar effects on miR-33b-negative 
medulloblastoma cells and miR-33b-positive medulloblastoma. Therefore miR-33b is an 





Fig. 13: Over-expression of miR-33b in Daoy cells down-regulates c-Myc and 
increase Gl cell cycle arrest. (A) Western blot analysis for protein levels of c-
Myc and its transcriptional targets Cyc1in E and ODC in Daoy cells transfected 
with vector or miR-33b. (B) Flow cytometry analysis to determine cell cycle 
progression of Daoy cells transfected with the parental vector or miR-33b. On 
the left is a representative photo of a single flow cytometry run with the y-axis 
denoting events (the number of cells) and the x-axis denoting the emitted 
fluorescence of the DNA dye (PI); a bar graph on the right is provided to 


















Fig. 14: miR-33b inhibits c-Myc-mediated cell proliferation and invasiveness of 
Daoy cells. (A) MTT cell proliferation assay of Daoy cells transfected with 
parental vector or miR-33b for 24,48 or 72 hrs. (B) QRT-PCR assay for the 
expression of miR-9 levels in Daoy cells transfected with miR-33n or vector. 
(C) Daoy cells transfected with mir-33b or vector for 48 hrs followed by 
Transwell migration assay. 
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2.3.8. miR-33b expression reduces tumorigenesis of D283 cells 
The soft agar colony forming ability of D283 cells was tested following stable 
transfection with either a vector control or miR-33b. D283 cells expressing miR-33b 
formed significantly less colonies on soft agar compared to D283 cells stably transfected 
with parental vector (Fig. 15). We then injected D283 cells constitutively expressing 
miR-33b or vector orthotopically into the cerebellum of immunodeficient nude (nu/nu) 
mice. Six weeks following injection, there was significantly less tumor expansion in brain 
ventricles of mice injected with cells carrying miR-33b compared to cells stably 
transfected with the parental vector (Fig 16A). As miR-33b is shown to down-regulate c-
Myc expression, we performed immunohistochemistry (IRC) on tumor sections to 
determine the expression level of c-Myc, Cyclin E, and sox2 proteins. miR-33b-
expressing D283 tumors expressed less c-Myc, Cyclin E and Sox2 compared to the 
control (Fig. 16B). Taken together, we conclude that miR-33b decreases 
medulloblastoma tumor growth via c-Myc-mediated inhibition of cell cycle progression 

















Fig. 15: miR-33b decreases anchorage-independent colony formation of D283 cells. 
D283 cells stably transfected with parental vector or miR-33b was grown on 0.5% soft-
agar for two week followed by MTT staining and imaged (magnification lOX). 
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Fig. 16: miR-33b reintroduction in D283 cells reduces tumorigenicity. (A) 
Hematoxylin Eosin (H&E) staining of mouse brain injected with D283 cells 
stably transfected with vector or miR-33b. Tumors are light blue; red dot 
donates blot vessels within tumors. (B) IHC ofD283 tumors from D283 cells 
stably transfected with the parental vector or miR-33b for the expression of c-
Myc, Cyc1in E and Sox2. Protein expression range is from brownish (high 
expression) to light blue (no expression). 
76 
2.4. DISCUSSION 
MYC codes for c-Myc, a transcription factor that regulates the expression of up to one 
third of human genes (185, 186). The genes regulated by c-Myc have placed it at the 
center of many biological processes, including apoptosis, cell cycle, differentiation and 
cellular proliferation (96, 211-215). It is now well established that c-Myc expression is 
essential for stern cell biology and inhibits differentiation of cells while favoring 
proliferation. The importance of c-Myc in carcinogenesis is also supported in animal 
models (216). c-Myc is viewed as an attractive target against cancer due to its crucial role 
in tumorigenesis. Despite early promise shown by drugs developed to target c-Myc, 
complete success is hampered by the lack of a good compound that inhibits c-Myc and 
low specificity of current chemotherapeutics against MYC. Therefore, understanding how 
Myc is regulated at all levels is critical for a more specific targeted therapy to be 
developed. The major goals of this work aimed at studying and identifying miRNAs that 
target MYC and how these miRNAs contribute to cancer development. We used a 2-tier 
luciferase screening method to systematically identify miRNAs that target the MYC 
gene. In tier-I, we made use of the c-Myc binding E2F2 promoter upstream of a 
luciferase gene. This enabled us to evaluate miRNAs that affected the MYC pathway. In 
tier-2, we cloned the 3'UTR of MYC downstream of a Rluc gene to evaluate which 
miRNAs directly target the 3'UTR of MYC. Using these E2F2-luc and MYC 3'UTR-
based Rluc constructs we screened 400 and 54 miRNAs, respectively, and showed that 
more than 25% of the miRNAs in each group adversely regulated MYC. Our luciferase 
results suggest that various miRNAs affect MYC directly as well as other components of 
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the MYC pathway. This result serves as a first step in elucidating miRNA targets in the 
MYC pathway. 
Using miR-210 as a control, we confirmed that our luciferase data are reliable since miR-
210 up-regulated the reporter assay from the E2F2-luc construct, consistent with a 
previous study showing that miR-21O targeted a c-Myc antagonist, MNT, to activate c-
Myc (217). Also, Let-7a and the miR-17-92 cluster of miRNAs target the MYC gene as 
reported previously (218, 219) and this is consistent with our luciferase data which 
showed that let-7a and members of the miR-17-92 cluster down-regulate the luciferase 
activity of both the E2F2-Luc and MYC 3'UTR based constructs. Our luciferase data 
suggest that miR-33b and miR-203 negatively regulated the luciferase reporter from the 
E2F2 promoter and the 3'UTR based constructs. However, only miR-33b over-expression 
resulted in down-regulation of c-Myc protein levels and this corresponded with decreased 
levels of c-Myc targets, Cyclin E and ODe. Also, we demonstrated an up regulation of 
Gadd45u, a gene that is repressed by c-Myc. The mRNA-miRNA binding usually results 
in either translational repression or mRNA degradation. Translational repression was 
believed to be the dominant mechanism observed for the majority of human miRNAs 
since perfect complementarity is hardly encountered (220). This observation are 
particularly true for mRNAs that have mUltiple binding sites to a given miRNA (220). 
However, when the miRNA has just one binding site to the mRNA's 3' UTR, speedy 
mRNA degradation is favored (220). We used qRT-PCR assay to reveal that miR-33b 
over-expression leads to lower steady state levels of MYC mRNA, favoring a mRNA 
degradation mechanism for this pair. 
78 
Other mechanisms likely contribute to c-Myc over-expression in medulloblastoma, as c-
Myc is over-expressed in -31-64% of cases (221-226), but the MYC gene is amplified in 
only 5-15% (94,99, 100). We show that miR-33b, a miRNA whose gene locus on 
chromosome 17p11.2 is characterized to be a major breakpoint in a subset (-17%) of 
medulloblastoma, regulates c-Myc expression and is sufficient to decrease 
medulloblastoma development via reduced cell proliferation, increased G 1 cell cycle 
arrest and decrease cell migration. Similar experiments were performed on a 
desmoplastic medulloblastoma cell line, Daoy, with similar results. Unlike the anaplastic 
D283 medulloblastoma cells which are characterized by loss of chromosome 17p 11.2 and 
over-expression of c-Myc (227, 228), the desmoplastic Daoy cells have an intact 
chromosome 17p11.2 locus and express miR-33b. This suggests that loss of miR-33b 
expression is a contributing factor to aggressiveness of tumor cell growth. Our data show 
that expression of miR-33b decreases tumorigenic properties such as proliferation, cell 
migration and cell cycle progression. Colony formation assays on soft agar show that 
miR-33b was able to reduce the number of D283 colonies compared to empty vector 
control. 
Medulloblastoma has been reported to have a stem cell origin (229). Medulloblastoma 
cells differentiate into numerous cell types, lending credence to its stem-like character. 
Furthermore, a group of cancer cells with the ability to self-renew and differentiate into 
all cell types continue to gain ground as the major culprit in tumor therapeutic resistance 
(230, 231). Development of therapies that could result in targeting the differentiated and 
the self-renewing cancer cells will significantly reduce relapses. We used D283 cells to 
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determine whether miR-33b expression will affect the stem cell characteristics of 
medulloblastoma. We show that stable re-introduction of miR-33b resulted in a 
morphological change in the D283 cells, from a multicell aggregate characteristic of stem 
cell to desegregated single-cell suspension characteristic of differentiated cells. miR-33b-
expressing D283 cells when placed in the neurobasal media that favors the growth of 
neural stem cells, formed smaller and lower number of neurospheres compared to the 
control. Expression of stem cell markers, MYC, SOX2, CD133, and Musashi was 
significantly reduced in miR-33b-expressing neurospheres and differentiated 
neurospheres compared to cells stably transfected with the parental vector. These results 
suggest that miR-33b targets both the differentiated cancer cells and the self renewing 
cells. To replicate our findings in vivo, D283 cells with stable expression of miR-33b or 
parental vector using lentivirus infection was injected into the cerebellum of 
immunodeficient nude mice to determine whether tumorigenesis is affected. miR-33b-
expressing D283 cells formed smaller tumors compared to D283 tumors from cells stably 
transfected with the parental vector. Expression levels of c-Myc, Cyclin E and Sox2 was 
down-regulated from D283 tumors expressing miR-33b. Differential expression of Cyclin 
E indicated that miR-33b acted as a cell cycle regulatory miRNA and functions through a 
c-Myc-mediated arrest in cell growth. 
In summary, data from these experiments suggest that miR-33b is a negative regulator of 
c-Myc, and its loss in a subset of medulloblastomas may contribute to c-Myc over 
production and tumor growth. 
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CHAPTER 3 
A STATIN-REGULATED MICRORNA REPRESSES C-MYC EXPRESSION AND 
FUNCTION 
3.1. INTRODUCTION 
RNA interference (siRNA) technology show great promise based on studies in 
mammalian cell-culture systems and animal in vivo models and is currently being 
extensively evaluated as a potential therapeutic strategy. The induction of immune 
response by siRNA (232) is a drawback of siRNA technology, as well as an observed 
increase in mortality, probably due to saturation of the miRNA-processing system. 
However, the valuable experience and the knowledge gained from siRNA-based therapy 
are used while design miRNA-based technologies. The rationale for using miRNAs as 
potential therapeutic targets is based on: (1) miRNAs are endogenous antisense 
regulatory molecules; (2) miRNA expression profiles can be used to diagnose disease 
states, and deregulated miRNAs contribute to the initiation and development of disease; 
(3) mouse models demonstrate that miRNAs play an important role in diseases; (4) 
miRNA expression levels respond to physiological stimuli; (5) miRNA expression 
profiles change when cells are treated with drugs in vitro; and (6) their small size (23-24 
nucleotides in length) makes them attractive for drug development. miRNAs are related 
to and function similarly to siRNA (233, 234), which was first identified by Fire et al. 
(235). Various miRNA-based therapies including anti-sense miRNAs (236), locked 
nucleic acid (234), antagomirs (237), virus vector expressing miRNA (232) and mimic 
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miRNAs (156) have been examined, with limited success. Many difficulties are 
encountered when considering miRNAs as therapeutic drugs including (1) the extensive 
number of targets one miRNA can regulate, (2) delivery to the disease site; (3) lack of 
tissue specificity; (4) the potential of the body eliciting an immune response against 
them; and (5) low stability in vivo since they may be degraded by endogenous RNases. 
Improving the stability of miRNA-based drugs is the major focus of drug design. 
Furthermore, to develop effective delivery systems, it is important to gain an in-depth 
understanding of cellular miRNA uptake, distribution and the biological activity at 
whole-body, organ, and cellular levels. To circumvent these difficulties, repurposing 
FDA-approved drugs is a more realistic proposition. Various studies have indicated 
differential miRNA expression profiles upon treatment of cells with various compounds 
(238, 239). For example, breast cancer cells resistant to doxorubicin (DOX) exhibit a 
pronounced deregulation of miRNA expression and altered expression of miRNA 
processing enzymes (238). It is therefore possible to modulate specific miRNA 
production with approved FDA compounds. However, two drawbacks must be 
considered: (1) validation of positive proof-of-concept clinical data for the repurposed 
compounds; (2) the ability of the drug to be delivered to the diseased site. 
Drug repurposing (also known as Drug re-profiling, Therapeutic Switching and Drug re-
tasking) refers to the development of existing drugs for new indications. These drugs may 
have (i) known therapeutic uses, (ii) failed to show efficacy in late stage clinical trials, 
without safety issues; (iii) stalled in development for commercial reasons; (iv) passed the 
point of patent expiry; or (v) are being explored in new geographical markets (240). 
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U sing drug repositioning, pharmaceutical companies have achieved a number of 
successes, for example Pfizer's Viagra in erectile dysfunction and Celgene's thelidomide 
in severe erythema nodosum leprosum (240). We hypothesize that drug repurposing via 
modulation of miR-33b expression will decrease proliferation of miR-33b-positive 
medulloblastoma cells. 
We used a miR-33b-positive medulloblastoma cell line to screen drugs in the NIH 
collection that up-regulated miR-33b and reduced cell proliferation, and specifically 
singled out lovastatin. We showed that lovastatin results in a reduction in cell 
proliferation of miR-33b-positive Daoy cells, an effect not significant in miR-33b-
negative D283 cells. The lovastatin-induced inhibition of Daoy cell proliferation 
correlated with an increase in miR-33b expression as well as a down-regulation of c-Myc 
expression. Also, Daoy tumor growth was significantly reduced in mice treated with 
lovastatin, and tumors expressed lower levels of miR-9, c-Myc and Cyclin E. Treatment 
with lovastatin and the methylation inhibitor 5-Azacytidine, which released methylation 
of the SREBF l-miR-33b promoter, increased sensitivity to lovastatin in HeLa cells, a cell 
line that showed reduced lovastatin sensitivity, via miR-33b up-regulation. 
3.2. MATERIALS AND METHODS 
3.2.1. Cell culture 
Medulloblastoma cells, D283 and DAOY, were purchased from ATCC and cultured in 
EMEM (Gibco, Carlsbad, CA) supplemented with 10% FBS and 0.1 % (v/v) Antibiotic-
Antimycotic (Cellgro, Manassas, VA). UW228 medulloblastoma cell line was the kind 
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gift of Dr. J.R. Silber (University of Washington, Seattle, WA) and were maintained in 
DMEMlF12 supplemented with 10% FBS and 0.1 % (v/v) antibiotic-Antimycotic 
(Cellgro, Manassas, VA). The human cervix carcinoma cell line (HeLa cells) was 
purchased from ATCC and cultured in DMEM (Gibco, Carlsbad, CA) supplemented with 
10% FBS and 0.1 % (v/v) Antibiotic-Antimycotic (Cellgro, Manassas, VA). All cell lines 
were cultured at 37°C in an atmosphere containing 5% C02. Transient and stable 
transfections were performed as previously described. 
3.2.2. Luciferase assay 
The LightSwitch Luciferase Assay Kit (SwitchGear, Menlo Park, CA) was used to 
determine whether lovastatin activates the SREBF 1 promoter. The SREBF 1 promoter was 
cloned upstream of a Rluc gene. Daoy and D283-Med cells in 96-well plates were 
transfected with the SREBFl-luc promoter construct (SwitchGear Genomics, Menlo 
Park, CA), an LDHA-PROM positive control (SwitchGear, Menlo Park, CA) and a 
negative control ROl-PROM (SwitchGear, Menlo Park, CA) in triplicate wells. The cells 
were treated 24 hrs following transfection with 0, 0.2, 2 or 10 ~M of lovastatin. 
Luciferase activity was measured 24 hrs later, using the LightSwitch Luciferase Assay 
Kit, per the manufacturer's instruction. Briefly, 100~1 of the assay solution, made-up of 
Ix substrate in assay buffer, was pippeted into each well and incubated in the dark for 30 
mins, followed by luciferase reporter measurement. Luciferase activity was normalized 
against values of the positive and negative control. 
3.2.3. Western blot analysis 
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Medulloblastoma cell lines D283, Daoy and UW228 (1 x 106 cells/well) cultured in 6-
well plates were treated with lovastatin (0, 0.2, 2, 10 11M) and total protein was extracted 
using 1X RIPA reagent (Cell Signaling Technology, Danvers, MA) containing 1X 
protease inhibitor cocktail (Sigma, St. Louis, MO) after 48 hrs. Total protein 
concentration was determined using the Bicinchoninic Acid (BCA) method (Thermo 
scientific, Rockford, IL) according to the manufacturer's protocol. Western blot for c-
Myc (Santa Cruz, Santa Cruz, CA; sc-40; diluted 1: 1000), Cyclin E (Santa Cruz, Santa 
Cruz, CA; sc-25303; diluted 1:1000), Gadd45a (Santa Cruz, Santa Cruz, CA; sc-6850; 
diluted 1:1000), ODC (Cell signaling; Danvers, MA; dilution 1:1000) and ~-Actin 
(Sigma, St. Louis, MO; AC-15; diluted 1:5000) expression was performed. HeLa cells in 
6 well plates were treated with lovastatin (0, 0.2, 2, 10 11M) or lovastatin (0.2 11M), 5-
Azacytidine (0.2 11M) or lovastatin (0.2 IlM)/5-azacytidine (0.2 11M) for 48 hrs. Total 
protein from treated cells was used for western blot analysis for c-Myc, Cyclin E, ODC, 
Gadd45a and ~-Actin expression. To determine whether exogenous miR-333b regulated 
c-Myc protein expression, HeLa cells (1 x 106cells/well) cultured in 6-well plates were 
transfected with 2.5 Ilg of pSIF, miR-33b, or miR-33bM. Total protein was used for 
western blot analysis for the expression of c-Myc, Cyclin E, Gadd45a, ODC, and ~­
Actin. 
3.2.4. Quantitative real-time PCR (qRT-PCR) 
We used TaqMan miRNA and gene expression assays (applied Biosystem inc., Forest 
City, CA) to detect the expression level of mature miRNAs and gene mRNA, 
respectively (198). U6 RNA and p-Actin mRNA was used for normalization. 
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Medulloblastoma D283, Daoy and UW228 cells were treated with lovastatin (0, 0.2, 2, or 
10 /lM) and TaqMan qRT-PCR was performed for the expression of miR-33b, MYC 
mRNA and SREBFl mRNA. We performed qRT-PCR using total RNA from Daoy cells 
treated with vehicle, lovastatin (O.2/lM), mevalonate (lOO/lM) or lovastatinlmevalonate 
to determine whether mevalonate inhibits lovastatin-induced up-regulation of miR-33b 
and SREBFl mRNA and down-regulation of MYC mRNA. For this, Daoy cells will be 
treated with vehicle, lovastatin, mevalonate and lovastatinlmevalonate for 48 hrs. Total 
RNA was then extracted using TriZol and TaqMan miRNA and gene expression assay 
was used to measure miR-33b/a, SREBF and MYC mRNA expression. To determine 
whether orthotopic brains tumors of Daoy and D283 treated with vehicle or lovastatin 
had differential levels of miR-33b and miR-9, total RNA was extracted using the TriZol 
reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's protocol. A total of 100ng 
of total RNA was used for TaqMan miRNA expression assay to measure the expression 
level of miR-33b and miR-9. To determine the effect of lovastatin on miR-33b 
expression, HeLa cells were treated with lovastatin (0, 0.2, 5 and 10 /lM) and qRT-PCR 
was performed 24 and 48hrs later for miR-33b and MYC mRNA expression. 
Furthermore, HeLa cells were treated with lovastatin (0.2/lM), Valproic acid (0.2/lM), 5-
Azacytidine (O.2/lM), lovastatinlvalproic acid or lovastatinl5-azacytidine for 48 hrs. Total 
RNA was extracted from treated cells and qRT-PCR performed for MYC mRNA and 
miR-33b expression. To determine whether exogenous miR-33b regulated the expression 
of c-Myc-mediated miR-9, HeLa cells were transfected with: empty vector or miR-33b; 
miRNA inhibitor negative control or anitisense-miR-33b. Total RNA was extracted from 
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these cells after 48 hrs and miR-9levels were determined using the miRNA Taqman real-
time PCR method as previously described 
3.2.5. MTT assay 
Daoy cells (3 x 104cells/well) were plated in 96-well plates and treated with 0.2 ~M of 
drugs in the NIH clinical collection (NCC) 1 and 2 in triplicate wells. MTT assay was 
performed after 48 hrs. Likewise, Daoy and D283 cells were treated in triplicate 96-well 
plate with lovastatin (0, 0.2, 2, 10 ~M) for 48 hrs followed by MTT assay. HeLa cells (3 
X 104 Cells/ well) were treated with lovastatin (0, 0.2, 2 and lO~M) for 48 hrs followed 
by MTT assay. To determine whether epigenetic regulation affects HeLa cells lovastatin 
sensitivity, HeLa cells (3 X 104 Cells/ well) in a 96-well plate were treated with vehicle 
or lovastatin (O.2~M) alone or with valproic acid (0.2~M) or 5-azacytidine (0.2~M) for 
48 hrs. Cell viability of treated cells was compared to normalized vehicle control. HeLa 
cells (3x104cells/well) in 96-well plates were transfected with O.l~g of pSIF, miR-33b in 
triplicate wells. MTT assay was performed at 2, 4 and 6 days post-transfection as 
previously described. Furthermore, HeLa cells were co-transfected with vector control or 
miR-33b and pcDNA3.1, pcDNA-MYC-MYC 3'UTR WT or pcDNA-MYC-MYC 
3'UTR mut. MTT assay was performed 48 hrs later to determine if exogenous c-Myc 
could rescue the miR-33b-induced decrease in cell proliferation. 
3.2.6. Apoptosis assay 
To determine whether exogenous over-expression of miR-33b increase apoptosis of HeLa 
cells, HeLa cells (lx104cells/well) in 12-well plates were transfected with 1 ~g of empty 
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vector or miR-33b. Equally, HeLa cells were co-transfected with vector or miR-33b and 
pcDNA MYC, pcDNA-MYC 3'UTR WT or mutant constructs in 12 well plates. 
Transfected cells were washed with IX PBS and suspended in 500 fll of fresh media at 
48, 72 and 144 hrs post transfection. PI (1 flglml) was added and cells incubated in the 
dark for 15 mins. Cells were analyzed by flow cytometry (Becton Dickinson, Franklin 
Lakes, NJ) within Ihr of staining. 
3.2.7. Cell cycle analysis 
Also, D283 and Daoy cells were treated with lovastatin (0, 0.2, 2, or 10 flM). The cells 
were collected 48 hrs later and flow cytometry was performed and cell cycle analyzed 
using FlowJo software (Tree Star Inc., Ashland, OR) as previously described. Likewise 
HeLa cells were treated with lovastatin (0, 0.2, 2, 10 or 40 flM) or 0.2 flM of lovastatin, 
5-azacytidine, or lovastatinl5-azacytidine for 48 hrs followed by cell cycle analysis. To 
determine the effect on cell cycle after over-expression of miR-33b, HeLa cells 
(lx104cells/well) in 12-well plates were transfected with Iflglwell pSIF, miR-33b or 
miR-33a. For each variable a minimum of 3 samples were quantified. 
3.2.8. Transwell cell migration assay 
Daoy and D283 cells were treated with 0.2 flM of lovastatin for 48 hrs. The cells were 
washed twice in IX PBS after 48 hrs and collected in serum-free EMEM media (Gibco, 
Carlsbad, CA). Transwell (Boyden) cell migration assay was then performed as 
previously described. Migrated cells were fixed with methanol for 10 mins and stained 
with 0.4% crystal violet for 2 hrs. Non-migrated cells on the upper side of the filter were 
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removed with a cotton swab, and the filters mounted on microscope glass slides. Images 
were captured using a Nikon Eclipse TE300 microscope and a Nikon Plan Fluor lOxO.30 
objective. The migrated cells were counted using the ImageJ software. To determine the 
effect of exogenous miR-33b on HeLa cells migration, HeLa cells (lx104 cells/well) 
were transfected with empty vector, miR-33b, miRNA inhibitor negative control or 
antisense miR-33b. Two days after transfection the HeLa cells were collected in fresh 
serum-free DMEM and Transwell assay performed. 
3.2.9. Tumor formation 
All animal experiments were conducted according to a protocol approved by the 
University of Louisville Animal Care and Use Committee (IACUC number: 08107). We 
used orthotopically medulloblastoma cell-induced mice tumor to determine whether our 
In Vitro data is replicable in an animal model. Daoy cells (5 x 106 cells/mice) were 
injected subcutaneously into 13 NCRNU-M nude mice. Briefly, the cells were 
trypsinized and washed twice in IX PBS. The cells were then resuspended in IX PBS 
containing 5% matrigel. The cells were then counted using the Countess meter 
(Invitrogen, Carlsbad, CA). A total of 5 X 106 cells in 400 J.lI of media were injected into 
each mouse (200 J.lI at each flank of the mice). The animals were monitored for the 
formation of tumors. Once tumor reached a volume of 200 J.lm, the mice were separated 
into 3 groups (4 animals per treatment group) and the mice were treated three times a 
week with 0, 0.2 or I mg/Kg by peritoneal injection. The tumor sizes were measured each 
week and volume calculated using the formula; Volume = (rrJ6) (length) (width) (height) 
for four weeks after which the mice were sacrificed, tumor sizes measured and tumors 
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removed. Also, miR-33b-positive medulloblastoma cell line Daoy and miR-33b-negative 
medulloblastoma cell line D283 (1 x 105 cell/mice) were injected orthotopically into the 
cerebellum of the 22 mice/cell line as previously described. The mice were housed and 
monitored for two weeks for any signs of distress. Two weeks after orthotopic injection, 
the mice were treated with vehicle (5 mice) or Imglkg of lovastatin (5 mice) per cell line 
by intraperitoneal injection. The mice were sacrificed after 4 weeks of lovastatin 
treatment and tumor weight measured relative to whole brain. The tumors were then 
incubated in 10% formalin for 3 days, embedded in paraffin and 5 IlM sections cut onto 
slides. H&E staining was performed to determine size of D283tumors from mice treated 
and Daoy tumors as previously described. Immunohistochemistry (lHC) was performed 
using sections from the tumor groups to determine expression level of c-Myc, Sox2, 
Cyclin E, PCNA and Caspase 7 as previously described. 
3.2.10. EpiTect methy qPCR assay 
The EpiTect methyl DNA restriction Kit (Qiagen, Frederick, MD) and the EpiTect 
Methyl qPCR Primer Assay for SREBFl (Qiagen, Frederick, MD) were used to 
determine the methylation status of the SREBFl promoter following treatment with 
lovastatin and lor 5-azacytidine according to the manufacturer's protocol. Briefly, HeLa 
cell were treated with vehicle, O.2IlM of lovastatin, 5-azacytidine or lovastatinl 5-
Azacytidine for 48 hrs. Genomic DNA was extracted using TriZol as per the 
manufacturer's instruction and the concentration measured by nanodrop software. The 
genomic DNA (1llg) was digested with a methyl sensitive, methyl dependent or methyl 
sensitive/dependent enzymes for 6 hrs. The digested DNA was them used as a template 
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SBRY (BioRad, Hercules, CA) for qRT-PCR using the SREBFl methyl primer. 
Methylation status was determined using the EpiTect methyl DNA methylation PCR data 
analysis tool (Qiagen, Frederick, MD). 
3.2.11. Statistics 
The experimental results were expressed as the mean ± standard deviation of at least 3 
independent experiments. Two-tail Student's t-test was performed with p:S0.05 (*) 
considered as statistically significant between the samples and their respective controls. 
3.3. RESUL TS 
3.3.1. Lovastatin up-regulates miR-33b expression and adversely impacts on c-Myc 
expression and function in medulloblastoma cells. 
We performed a small scale screening assay to identify FDA-approved compounds that 
reduce medulloblastoma cell viability and increase miR-33b expression using Daoy, a 
medulloblastoma cell line with intact 17pl1.2 and with no gene amplification of MYC 
(100, 241). We singled out lovastatin (Fig. 17) as (i) its resulted in inhibition of Daoy 
cell proliferation by more than 40% and up-regulated miR-33b expression by 2.8 fold; (ii) 
its safety and efficacy has been tested for over thirty years; (iii) statins are reported to 
reduce cancer risk (242, 243); and (iv) statins or other cholesterol-lowering approaches 
up-regulate miR-33a, the homolog of miR-33b (244-247). MTT cell 
proliferation/viability assay was performed after Daoy or D283 cells were treated with 
increasing concentration of Lovastatin. The decrease in cell proliferation was lovastatin 
dose-dependent in Daoy but did not affect the proliferation of D283 cells (Fig. 18). 
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Fig. 17: Lovastatin most significantly resulted in reduced Daoy cell proliferation 
and up-regulation of miR-33. A small scale screening assay to identify FDA-
approved compounds that reduce medulloblastoma Daoy cell proliferation and 
















Fig. 18: Lovastatin dose-dependent decrease in Daoy, but not D283, cell 
proliferation. D283 and Daoy cell treated with lovastatin for 48 hrs followed by MTT 
cell proliferation/viability assay. 
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A qRT-PCR assay showed that in Daoy cells, lovastatin induced miR-33b and SREBFl 
expression in a dose-dependent manner, while MYC mRNA was down-regulated (Fig. 
19A). Yet there was no significant change in MYC mRNA levels upon lovastatin 
treatment in D283 cells (Fig. 19C). We tested the promoter of the human SREBF1-miR-
33b gene and found that lovastatin increased the promoter activities (Fig. 20A). In 
addition, mevalonate inhibited the induction of miR-33b and SREBFl and MYC mRNA 
down-regulation by lovastatin in Daoy cells (Fig. 20C), suggesting lovastatin activates 
miR-33b through the cholesterol biosynthetic pathway. In D283 cells, mevalonate did 
not affect the expression of MYC mRNA (Fig. 20B). Using other statins, we found that 
miR-33b expression was also increased but in a less significant manner compared to 





































0 0 0.2 2 
lovastatin (11M) 
9 o MYC 
o 
Fig.19: Lovastatin positively modulates miR-33b expression in miR-33b-positive 
medulloblastoma cells Daoy and UW228. (A) QRT-peR to measure the levels 
of miR-33b, SREBFl and MYC mRNA in Daoy cells treated with lovastatin for 
48 hrs. (B) QRT-peR to measure the levels of miR-33b, SREBFl and MYC 
mRNA in UW228 cells treated with lovastatin for 48 hrs. (e) MYC mRNA 
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Fig. 20: Lovastatin increases miR-33b transcription through the cholesterol 
synthetic pathway. (A) Luciferase activity from an SREBFlpromoter 
luciferase construct in Daoy and D283 cells treated in response to lovastatin. (B) 
MYC mRNA expression levels in D283 cells treated with lovastatin and/or 
mevalonate was determined by TaqMan qRT-PCR. (C & D) TaqMan qRT-PCR 
was used to determine the expression levels of miR-33b, SERBFl and MYC 
mRNA from Daoy cells treated with lovastatin and/or mevalonate. 
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Fig. 21: Impact on cell proliferation and miR-33b expression by other statins in 
Daoy cells. Daoy cells were treated with 0.2 ~M of various statins, and cell proliferation 
and miR-33b levels were determined. miR-33b was up-regulated by Simvastatin, 
Pravastatin, Cerivastatin, and Pitavastatin. 
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Correspondingly, lovastatin caused reduction in c-Myc, Cyclin E and ODC protein levels 
and up-regulation of Gadd45a in Daoy (Fig. 22A) but not in D283 cells (Fig. 22B). We 
also treated UW228 (another cell line with an intact 17p 11.2) with lovastatin and found 
there was a significant induction of miR-33b and SREBF1, and a decrease in MYC 
mRNA expression in UW228 cells (Fig. 19B). Equally, protein levels of c-Myc and its 
transcriptional targets Cyclin E and ODC are down-regulated in a dose-dependent 
manner by lovastatin in UW228 cells, while Gadd45a was up-regulated (Fig. 22A) This 
is in line with a previous report that Daoy and UW228 are more sensitive to lovastatin 
than D283 (248). Cell cycle analyses demonstrated that more Daoy but not D283 cells 
had delay G 1 phase progression upon lovastatin treatment (Fig. 23). Lovastatin resulted 
in decreased levels of miR-9 (Fig. 24A) and a corresponding reduction in cell migration 
of Daoy cells (Fig. 24B) but did not affect miR-9 (Fig. 24A) levels or cell migration of 
D283 cells (Fig. 25B). 
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Fig. 22: Lovastatin down-regulates the protein expression of c-Myc and its 
transcriptional target in miR-33b-positive medulloblastoma Daoy and 
UW228 cells. (A) Western blot analysis for the expression of c-Myc, Cyclin E, 
ODC and Gadd45a in response to lovastatin treatment of miR-33b-positive 
Daoy and UW228 cells. (B) Protein levels of c-Myc and its target Cyclin E, 
ODC and Gadd45a determine by western blot in miR-33b-negative D283 cells 
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Fig. 23: Lovastatin increase Gl cell cycle arrest in Daoy, but not D283, cells. Cell 
cycle analyses of Daoy (left) and D283 (right) cells treated with lovastatin. 
Lovastatin induces significant G 1 phase cell cycle arrest in Daoy cells but not 
D283 cells. On the top is a representative photo of a single run with the y-axis 
denoting events (the number of cells) and the x-axis denoting the emitted 
fluorescence of the DNA dye (PI); the bar graph on at the bottom summarizes 
three independent runs. "0-1 0 ~M" indicates the final concentration of 
lovastatin 
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Fig. 24: Lovastatin decrease cell invasiveness of miR-33b-positive medulloblastoma 
Daoy cells. (A) miR-9 expression levels, assayed by qRT-PCR, in Daoy and 
D283 cells treated with vehicle or lovastatin. Lovastatin results in down-
regulation of miR-9 in Daoy cells, but not D283. (B) Transwell cell migration 
assay of Daoy and D283 cells treated with vehicle or lovastatin. The upper panel 
is a representative photo of migrated cells; the bottom panel is the bar graph 
summarizing three independent experiments. 
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3.3.2. Lovastatin decrease tumor growth of miR-33b-postive medulloblastoma Daoy, 
but not D283, cells in immunodeficient nu/nu mice 
We treated mice subcutaneously injected with Daoy cells to form xenografts and found 
either 1.0 mglkg or 0.2 mglkg of lovastatin treatment resulted in smaller tumor sizes (Fig. 
25A) and lower c-Myc expression (Fig. 26D). We then tested whether lovastatin reduces 
the brain tumor burden in an orthotopic model, which requires testing compounds to 
penetrate the blood-brain barrier (BBB), a separation of circulating blood and 
cerebrospinal fluid in the central nervous system. Lovastatin is lipophilic and is able to 
penetrate the BBB, and this comes with some side effects such as sleep disturbances 
(249,250). We inoculated Daoy or D283 cells into the brain of immunodeficient mice 
and treated them with 1.0 mglkg of lovastatin. At the end of regimen (4 wks), all Daoy-
bearing mice in the control group became moribund or paralyzed; yet mice in the 
lovastatin group appeared physically normal. We found that Daoy-xenografted mice 
treated with lovastatin had less tumor expansion in the ventricles; and strikingly, tumor 
invasion into the surrounding cerebellar tissues was completely blocked (Fig. 25B). In 
contrast, D283 xenograft neither invaded surrounding tissues nor responded to lovastatin 
treatment (Fig.25B). Lovastatin treatment led to miR-33b up-regulation (Fig. 26B) and 
lowered expression of miR-9 (Fig. 26A), c-Myc, and Cyclin E in tumors of Daoy (Fig. 
26C) but not in that of D283 cells (Fig. 26A & C). There was no statistically significant 
change in the percentage of PCNA-positive cells in control tumors versus treated Daoy 
tumors (Fig. 26C), suggesting cell cycle arrest rather than apoptosis is a likely cause for 







































Fig. 25: Xenograft models of medulloblastoma with lovastatin treatment. (A) 
Subcutaneous tumor growth rate of Daoy tumors in vehicle or lovastatin treated 
nu/nu mice. (B) A representative H&E staining of the brain from mice, 
orthotopically injected with Daoy or D283 cells, treated with vehicle or 
lovastatin (left). Average surface area from tumors in vehicle or lovastatin 





• D283-Med Tumor 





Vehicle Lovastatin (O.2j.1M) 0"------: 







Fig. 26: Lovastatin treatment led to miR-33b up-regulation and lowered expression 
of miR-9, c-Myc, and eyelin E in Daoy tumors. (A & B) The expression of 
miR-9 from Daoy and D283 tumors from mice treated with vehicle or lovastatin 
(A) The levels ofmiR-33b from Daoy tumor from vehicle or lovastatin treated 
mice (B). (C) IHC analyses of orthotopic tumor of Daoy or D283 cells. (D) IHC 
analyses of c-Myc expression in subcutaneous Daoy tumor sections. 
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3.3.3. The methylation inhibitor 5-azacytidine sensitize HeLa cells to lovastatin-
induced inhibition of cell growth 
There was no change in proliferation of HeLa cell treated with increasing concentration 
of lovastatin (0, 0.2, 2, or 10 /lM), except at the high concentration of 40 /lM (Fig. 27 A), 
a concentration used to synchronize HeLa cells at G 1 phase of the cell cycle (251). QRT-
PCR shows that in HeLa cells, lovastatin did not affect the levels of miR-33b and MYC 
mRNA (Fig. 27B & C). Correspondingly, lovastatin did not affect the protein levels of c-
Myc and its target gene Cyclin E, ODC and Gadd45a (Fig. 27D). Cell cycle analysis 
revealed that at a concentration up to 10 /lM there was no change in cell cycle 
progression (Fig. 28B). Using FDA-approved drugs that were found to up-regulate miR-
33b in Daoy cells, qRT-PCR using RNA from HeLa cells treated with 0.2 /lM of these 
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Fig. 27: HeLa cells show reduced sensitivity in response to lovastatin treatment. (A) 
MTT cell proliferation assay of HeLa cell in response to lovastatin treatment for 
48 hrs. '0-1011' denotes low therapeutic concentration range; '40IlM' donates 
high concentration (B & C) QRT-PCR assay shows the level of miR-33b (B) or 
MYC mRNA (C) in HeLa cells response to lovastatin. (D) Protein levels of c-
Myc and its transcriptional targets Cyc1in E, ODC and Gadd45a in HeLa cells 
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Fig. 28: Expression of miR-33b is lower in HeLa cells compared to Daoy cells in 
response to FDA approved drugs. (A) Differential expression ofmiR-33b in 
response to drugs that significantly decrease medulloblastoma Daoy cell 
proliferation. (B) Flow cytometry analysis for cell cycle progression of HeLa 
cell treated with lovastatin for 48 hrs. On the left is a representative photo of a 
single run with the y-axis denoting events (the number of cells) and the x-axis 
denoting the emitted fluorescence of the DNA dye (PI); the bar graph on the 
right summarizes three independent runs. "0-10 IlM" indicates the final 
concentration of lovastatin. 
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HeLa cell proliferation was significantly reduced in response to valproic/lovastatin acid 
or 5-azacytidine/lovastatin treatments compared to lovastatin, valproic acid, 5-azacytidine 
or vehicle treatment alone (Fig 29A). The reduced proliferation corresponded with up-
regulation of miR-33b expression and decreased MYC mRNA (Fig 29B & C). 
Furthermore, c-Myc, Cyclin E and ODC protein expression levels were down-regulated, 
and Gadd45a expression was up-regulated in HeLa cells treated with 5-
azacytidinellovastatin (Fig. 29D). Cell cycle analysis show that 5-azacytidine/lovastatin 
increased Gl cell cycle arrest (Fig. 30B). A methylation assay demonstrates that 5-
azacytidine decrease the methylation status of the SREBF1-miR-33b promoter to levels 
comparable to lovastatin sensitive Daoy cells (Fig. 30A). These results suggest that 
methylation on the SREBF1-miR-33b promoter might contribute to reduced lovastatin 
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Fig. 29: 5-Azacytidine sensitizes HeLa cells to lovastatin-induced inhibition of cell 
proliferation. (A) Cell proliferation of HeLa cells was determined by MTT cell 
proliferation assay following treatment with vehicle, lovastatin and/or 5-
azacytidine for 48 hrs_ (B & C) HeLa cells expression of miR-33b (B) and MYC 
mRNA (C) assayed by qRT-PCR upon vehicle, lovastatin and/or 5-azacytidine 
treatment. (D) Western blot analysis for expression of c-Myc, Cyclin E, ODC 
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Fig. 30: 5-Azacytidine treatment decreases the methylation level of the SREBF1-
miR-33b gene enable lovastatin-mediated Gl cell cycle arrest of HeLa cells. 
(A) Methylation status was determined by SYBR green peR using SREBFl 
methyl specific primer following enzymatic digestion of HeLa cell genomic 
DNA extracted from cells treated with vehicle, lovastatin andlor 5-azacytidine 
(B) Flow cytometry analysis for cell cycle progression of He La cell treated with 
vehicle, lovastatin and/or 5-azacytidine. On the left is a representative photo of a 
single run with the y-axis denoting events (the number of cells) and the x-axis 
denoting the emitted fluorescence of the DNA dye (PI); the bar graph on the 
right summarizes three independent runs. "0-10 f.!M" indicates the final 
concentration of lovastatin. 
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3.3.4. miR-33b down-regulates endogenous c-Myc expression and adversely affect its 
function in HeLa cells 
Next, we determined the expression of c-Myc and its transactivational targets in HeLa 
cells following miR-33b over-expression. We found down-regulation of c-Myc, Cyclin 
E, ODC (Fig. 31A), and miR-9 (Fig. 33A), a miRNA regulated by c-Myc (252) and up-
regulation of Gadd45a (Fig. 31A) by miR-33b but not by miR-33bM in HeLa cells, 
similar to that in 293T cells. Additionally, MYC rnRNA levels were reduced in response 













Fig. 31: Modulation of miR-33b expression in HeLa cells reciprocally modulates c-
Myc protein and MYC mRNA expression. (A) Western blot analysis for the 
expression of c-Myc and its target Cyc1in E, ODC and Gadd45a from HeLa 
cells transfected with the parental vector, miR-33b or miR-33b mutant construct 
for 48 hrs. (B) qRT-PCR to determine levels of MYC mRNA from HeLa cells 
transfected with the parental vector or miR-33b. (C) Protein levels of c-Myc, 
Cyc1in e and Gadd45a assayed by western blot following HeLa cell transfection 
with a negative control anti-sense miRNA or anti-sense miR-33b for 48 hrs. 
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As cyclin E expression is required for G 1-S phase transition during cell cycle, we 
perfonned cell cycle analyses using flow cytometry. As shown in Fig. 32A, miR-33b, 
but not miR-33bM or the control resulted in more cells arrested at the G1 phase. 
Moreover, as c-Myc is reported to promote cell proliferation, and cell migration (100, 
211-213,215), we perfonned MTT, and Transwell assays to detennine whether these c-
Myc functions in HeLa cells were compromised by miR-33b. As expected, cells with 
miR-33b over-expression have a significant reduction in cell proliferation (Fig. 32B), and 
cell migration (Fig. 33B), indicating miR-33b down-regulate endogenous c-Myc 
expression and adversely affect c-Myc function in HeLa cells. We also inhibited miR-
33b expression using modified antisense oligonucleotides against miR-33b (Anti-miR-
33b) and found that the expression of c-Myc was up-regulated, so did cyclin E (Fig. 
31C), amnd miR-9 (Fig. 33A) whereas Gadd45a was down-regulated (Fig. 31C). Cell 
migration was increased when miR-33b was inhibited (Fig. 33B). We next detennine 
whether exogenous expressed c-Myc could rescue apoptosis induced by miR-33b. We 
co-transfected cells with a c-Myc-expressing construct with a WT or a mutant 3'UTR and 
miR-33b. Flow cytometry results show that exogenous c-Myc, with the mutant UTR 
(which is not targeted by miR-33b) but not that with WT, is able to rescue apoptosis 
caused by miR-33b over-expression (Fig. 34). These results demonstrate that miR-33b 
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Fig. 32: Over-expression of miR-33b down-regulated c-Myc-mediated functions in 
HeLa cells. (A) Flow cytometry of He La cells transfected with a parental 
vector, miR-33b or miR-33b mutant to determine cell cycle progression. On top 
is a representative photo of a single run with the y-axis denoting events (the 
number of cells) and the x-axis denoting the emitted fluorescence ofthe DNA 
dye (PI); the bar graph at the bottom summarizes three independent runs. (B) 
HeLa cell proliferation following HeLa cell transfection with the parental vector 
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Fig. 33: Modulation of rniR-33b inversely correlates with HeLa cells invasiveness. 
(A) Expression level of miR-9 in HeLa cells determined by TaqMan qRT-PCR. (B) 
Transwell cell migration assay of HeLa show that miR-33b expression inversely 
correlates cell migration. 
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Fig. 34: miR-33b-induced apoptosis is rescued by exogenous c-Myc expression (~ 
indicates significance of <0.05 between pSIF transfected group: * represent significance 
of <0.05 between pSIF and miR-33b transfected groups). HeLa cells were co-transfected 
with MYC 3'UTR WT or mutant constructs and pSIF or miR-33b and 48 hrs later, flow 
cytometry was performed to determine cellular apoptosis. 
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3.4. DISCUSSION 
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, 
blocks the mevalonate pathway, decreasing cholesterol biosynthesis as well as the 
production of non-steroidal mevalonate derivatives (253). Lovastatin has profound 
cellular effects, including inhibition of proliferation and induction of apoptosis of cancer 
cells (254, 255), including medulloblastoma cells (256), and has been used as a potential 
anticancer drug in clinical studies (257, 258). In this study, we show that lovastatin can 
be used against tumors through modulation of an miRNA targeting c-Myc. As described 
earlier, medulloblastoma show over-expression of c-Myc in 64% of cases but only 10-
15% show MYC genomic amplification. The second major characteristic is that a subset 
(-17%) has a major breakpoint on chromosome 17p11.2, which results in chromosomal 
deletion at the breakpoint (259). One of the genes found in this deleted region is 
SREBF1-miR-33b, which is important in lipid metabolism and harbors miR-33b on 
intron 17. Interestingly, medulloblastoma cells that have this chromosome breakpoint 
show lower sensitivity to lovastatin treatment (256). We show that lovastatin treatment of 
medulloblastoma cell line Daoy results in a significant reduction in cell proliferation, an 
effect not observed in D283 cells. Lovastatin-induced inhibition of Daoy cell 
proliferation correlated with an increase in miR-33b expression as well as a down-
regulation of c-Myc expression. Treatment of mice with lovastatin resulted in a 
significant reduction of Daoy tumor growth. Concordantly, the tumors expressed lower 
levels of miR-9, c-Myc and Cyclin E. This, to our knowledge, is the first evidence of 
pharmaceutical modulation of c-Myc via a miRNA, and provides a new approach to 
cancer therapy by targeting miRNA with repurposed drugs. 
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Sensitivity to lovastatin is cell-type specific (260). In the case of HeLa cells, lovastatin 
treatment has no effect on miR-33b expression. We hypothesize that epigenetic silencing 
of the SREBF 1 gene promoter is responsible for the reduced lovastatin sensitivity. In 
mammals, the best understood epigenetic modification of DNA is post-replicative 
methylation of the C5 position of cytosine residues in CpG dinucleotides. We did find 
the SREBF1 promoter was significantly methylated in HeLa cells, but not in Daoy cells. 
5-Azacytine is an FDA-approved antitumor drug that acts as a methyltransferase 
inhibitor, that prevents epigenetic gene silencing (261,262). When HeLa cells were 
treated with 5-Azacytidine along with lovastatin, miR-333b was up-regulated and MYC 
was down-regulated. This was accompanied with decreased methylation of the SREBF1 
promoter, as well as suppression of c-Myc-mediated cell proliferation, cell migration and 
cell cycle progression. 
In summary, we have documented here that lovastatin represses the oncogenic activities 
of c-Myc through activation of miR-33b transcription. Furthermore, lovastatin sensitivity 




Tumor development is hallmarked by a variety of genetic and epigenetic alterations in 
protein-coding genes and small non-coding RNA genes. MYC is a major oncogene 
encoding the transcription factor c-Myc. miRNAs are a diverse family of small RNAs 
that regulate the stability and translational efficiency of partially complementary target 
mRNAs (263, 264). By regulating specific oncogenes or tumor-suppressor molecules, 
these small RNAs may have profound effects in tumor development (265). A few target 
genes have been validated for some miRNAs, and each individual miRNA can target 
mUltiple genes and participate in diverse physiological or pathological functions. In this 
study we aimed at elucidating miRNAs that target MYC. Using an array of molecular 
techniques including reporter assays, western blot analysis, cell cycle analysis, cell 
migration and cell proliferation assays, we showed that MYC is a miR-33b target gene. 
Medulloblastoma is characterized by an over-expression of c-Myc. While 64% of 
medulloblastomas have over-expression of c-Myc, yet only 5-15% of medulloblastomas 
show MYC gene amplification (96, 266). Myc over-expression is a biomarker associated 
with poor prognosis of medulloblastoma, along with chromosome 17p breakpoint 
abnormalities. Interestingly, Myc over-expression without genomic amplification is 
mostly observed in the more aggressive and metastatic anaplastic subtype of 
medulloblastoma (96,267-269). The human miR-33b gene is located in intron 17 of the 
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SREBF J-miR-33b gene and this genomic locus, 17pl1.2, is frequently lost in 
medulloblastoma (44, 228, 270). Breakpoints on chromosome 17p, similar to that in 
Smith-Magenis syndrome, present in medulloblastoma either leads to complete deletion 
of this chromosomal regions or it is translocated to chromosome 17 q thereby forming an 
isochromosome i17q (227). We have determined that miR-33b targets MYC and 
adversely affects its biological functions in medulloblastoma. Therefore the loss of miR-
33b expression could in part explain the over-expression of c-Myc in a subset of 
medulloblastoma. Various functional assays were used to show that re-introduction of 
miR-33b in anaplastic medulloblastoma D283 cells negatively affects medulloblastoma 
tumorigenic proporties by reducing cell proliferation, cell migration, and cell cycle 
progression. Using neurosphere assays, immucytochemistry and qRT-PCR, we show that 
miR-33b re-introduction results in reduction of neurospheres formed by medulloblastoma 
D283 cells and down-regulation of stem cell markers such as CD133, SOX2, Musashi 
andMEKL. 
We decided to use drug repurposing to elevate miR-33b and inhibit c-Myc. We 
performed a small scale screening of FDA-approved drugs and found that lovastatin 
inhibits cell growth and increases miR-33b levels in Daoy cells. Lovastatin down-
regulated c-Myc expression and led to Gl arrest in the miR-33b-positive Daoy cells, but 
not in the miR-33b-null D283 cells. The change in miR-33b expression upon lovastatin 
treatment reciprocally corresponded with c-Myc expression. These results suggest that 
lovastatin acts in part as an activator of miR-33b expression, which, in tum, decreases 
cellular proliferation through suppression of the MYC gene. We then tested whether 
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lovastatin reduces the brain tumor burden in an orthotopic model, which requires the 
testing compounds to penetrate the blood-brain barrier (BBB), a separation of circulating 
blood and cerebrospinal fluid in the central nervous system. Lovastatin is lipophilic and 
is able to penetrate the BBB (250,271). We found that lovastatin slows the growth of 
tumors inoculated with Daoy, but not that with D283 (a miR-33b-negative cell line). 
This suggests a therapeutic option against medullablastoma with lovastatin using miR-
33b as a biomarker. 
However, not all cell lines are responsive to lovastatin, one of which is HeLa. This 
could be due to hypermethylation of the promoter to SREBF1, the host gene for miR-33b 
(272). We did find that this promoter is methylated at a higher level in HeLa compared 
with Daoy cells. When treated with a methylase inhibitor, 5-azacytidine, HeLa cells 
became sensitive to lovastatin, along with reduced methylation of the promoter. In 
addition, increased sensitivity to lovastatin correlated with up-regulation of miR-33b and 
down-regulation of c-Myc expression in HeLa cells treated with 5-azacytindine. These 
results suggest that DNA hypermethylation of the SREBFl promoter is the underline 
mechanism of 10vastatin insensitivity in HeLa cells. 
Taken together, this study has: (i) identified that miR-33b targets MYC; (ii) suggested that 
miR-33b loss may contribute to c-Myc over-expression in some medulloblastomas; (iii) 
revealed that 10vastatin is an attractive chemotherapeutic agent against medulloblastoma 
with a native miR-33b gene; (iv) shown that the resistance of 10vastatin in HeLa cells is 
likely a result of epigenetic inactivation of the SREBFl ~miR-33b gene; and (v) presented 
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a highly promising therapeutic option, using drug repurposing and a miRNA as a 








Fig. 35: Proposed schematic of lovastatin induce inhibition of medulloblastoma cell 
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Appendix II 
Abbr - Full 
3 'UTR - 3' Untranslated Region 
APC - Polyposis Coli 
AR -Average Risk 
bHLHZip - Basic Helix-Loop-Helix Leucine Zipper 
CDC25A - Cell Division Cycle 25A 
CDK - Cyclin Dependent Kinase 
CGH - Comparative Genomic Hybridization 
CKla - Casein Kinase la 
CLL - Chronic Lymphocytic leukemia 
CNS - Central Nervous System 
CRT - Conformal Radiation Therapy 
CSC - Cancer Stem Cell 
CSRT - Craniospinal Radiatherapy 
CT - CAT scan 
Dsh - Dishevelled 
E2F 112 - E2 promoter binding Factor 112 
EGFR -Epidermal Growth Factor Receptor 
EGL - External granular layer 
ES - Embryonic Stem cells 
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FBW7 - F-box and WD repeat domain containing 7 
GFP - Greem Fluorescent Protein 
GSK-3p - Glycogen Synthase Kinase -3P 
HAT - Histone acetyl Transferase 
HGF - Hepatocyte Growth Factor 
HGMA2 - high mobility group AT-hook 2 
HIF-l - Hypoxia-Inducible Factor! 
HR - High Risk 
HSC - haematopoietic Stem cell 
IGFR - Insulin-like Growth Factor Receptor 
IQ -Intelligence Quotient 
LAIC - Large/anaplastic medulloblastoma 
LDL - Low density lipoprotein 
LR-Lowrisk 
LRP - LDL Receptor-related Protein 
MB -Myc-Box 
MBEN -Medulloblastoma with extensive nodularity 
miRNA - MicroRNA 
MRI - Magnetic resonance Imaging 
Mut-Mutant 
ncRNA - Non-coding RNA 
NSC - Neural Stem Cell 
nt - Nucleotide 
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ODC - Ornithine Decarboxylase 
PDCD4 - programmed Cell Death 4 
PDGFR - Platelet-derived growth Factor receptor 
PI3K - Phosphatidylinositol-3-kinase 
PNET - Primitive neuroectodennal tumor 
PNK -Polynucleotide Kinase 
RB - Retinoblastoma 
RFP (mKate) - Red Fluorescent Protein 
RISC - RNA-Induced Silencing Complex 
ROS -Reactive Oxygen Species 
RTK - Receptor Tyrosine Kinase 
SC - Stem cell 
Shh - Sonic Hedgehog 
SREBFl - Sterol Regulatory Element Binding Transcription Factor 1 
TAD - Transactivation domain 
TcfILef - T-cell factor/lef 
TGFB - Transfonning Growth Factor B 
TIC - Tumor Initiating Cell 
TRK - Tyrosine Kinase 
VEGF - Vascular endothelial Growth Factor 
WHO - World Health Organization 
Wnt - wingless 
WT -Wild type 
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ZEB - Zinc finger E-box binding Factor 
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